

Gerhard Rogler

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3225626/publications.pdf>

Version: 2024-02-01

589
papers

30,175
citations

4942

84
h-index

9311

143
g-index

627
all docs

627
docs citations

627
times ranked

30137
citing authors

#	ARTICLE	IF	CITATIONS
1	Challenges in the Pathophysiology, Diagnosis, and Management of Intestinal Fibrosis in Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2022, 162, 26-31.	0.6	48
2	Depressive Symptoms Predict Clinical Recurrence of Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 560-571.	0.9	20
3	New Therapeutic Approach for Intestinal Fibrosis Through Inhibition of pH-Sensing Receptor GPR4. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 109-125.	0.9	10
4	Ingested nano- and micro-sized polystyrene particles surpass the intestinal barrier and accumulate in the body. <i>NanoImpact</i> , 2022, 25, 100374.	2.4	20
5	Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 254-261.	3.7	18
6	pH-Sensing G Protein-Coupled Receptor OGR1 (GPR68) Expression and Activation Increases in Intestinal Inflammation and Fibrosis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1419.	1.8	9
7	Effectiveness of golimumab in patients with ulcerative colitis: results of a real-life study in Switzerland. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482210741.	1.4	5
8	Inhibition of integrin $\alpha 6 \beta 1$ sparks T-cell antitumor response and enhances immune checkpoint blockade therapy in colorectal cancer. , 2022, 10, e003465.		15
9	IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: The PROCTRIAL Consensus. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2619-2627.e1.	2.4	9
10	The Intestinal Barrier—Shielding the Body from Nano- and Microparticles in Our Diet. <i>Metabolites</i> , 2022, 12, 223.	1.3	12
11	Gut microbiome and circulating bacterial DNA (œblood microbiome) in a mouse model of total parenteral nutrition: Evidence of two distinct separate microbiotic compartments. <i>Clinical Nutrition ESPEN</i> , 2022, 49, 278-288.	0.5	5
12	Lipid emulsion rich in n-3 polyunsaturated fatty acids elicits a pro-resolution lipid mediator profile in mouse tissues and in human immune cells. <i>American Journal of Clinical Nutrition</i> , 2022, 116, 786-797.	2.2	9
13	Endothelial Barrier Disruption by Lipid Emulsions Containing a High Amount of N3 Fatty Acids (Omegaven) but Not N6 Fatty Acids (Intralipid). <i>Cells</i> , 2022, 11, 2202.	1.8	0
14	Novel Strategies to Prevent Total Parenteral Nutrition-Induced Gut and Liver Inflammation, and Adverse Metabolic Outcomes. <i>Molecular Nutrition and Food Research</i> , 2021, 65, e1901270.	1.5	14
15	Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 106-122.	0.9	14
16	Varicella Zoster Virus in Inflammatory Bowel Disease Patients: What Every Gastroenterologist Should Know. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 316-325.	0.6	5
17	Contribution of CD3+CD8- and CD3+CD8+ T Cells to TNF- α Overexpression in Crohn Disease—Associated Perianal Fistulas and Induction of Epithelial-Mesenchymal Transition in HT-29 Cells. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 538-549.	0.9	11
18	Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 6 816-825.	0.9	18

#	ARTICLE	IF	CITATIONS
19	Nutritional Lipids and Mucosal Inflammation. <i>Molecular Nutrition and Food Research</i> , 2021, 65, e1901269.	1.5	20
20	Choice of Lipid Emulsion Determines Inflammation of the Gut-Liver Axis, Incretin Profile, and Insulin Signaling in a Murine Model of Total Parenteral Nutrition. <i>Molecular Nutrition and Food Research</i> , 2021, 65, e2000412.	1.5	8
21	Solute Carrier Family 12 Member 2 as a Proteomic and Histological Biomarker of Dysplasia and Neoplasia in Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 287-298.	0.6	4
22	Effects of anti-TNF therapy and immunomodulators on anxiety and depressive symptoms in patients with inflammatory bowel disease: a 5-year analysis. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110337.	1.4	6
23	A Novel OGR1 (GPR68) Inhibitor Attenuates Inflammation in Murine Models of Colitis. <i>Inflammatory Intestinal Diseases</i> , 2021, 6, 140-153.	0.8	13
24	Protein tyrosine phosphatase nonreceptor type 2 controls colorectal cancer development. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	16
25	Dysbiotic microbiota interactions in Crohn's disease. <i>Gut Microbes</i> , 2021, 13, 1949096.	4.3	38
26	Hypoxia Reduces the Transcription of Fibrotic Markers in the Intestinal Mucosa. <i>Inflammatory Intestinal Diseases</i> , 2021, 6, 87-100.	0.8	0
27	Abdominal pain in patients with inflammatory bowel disease: association with single-nucleotide polymorphisms prevalent in irritable bowel syndrome and clinical management. <i>BMC Gastroenterology</i> , 2021, 21, 53.	0.8	11
28	Perianal fistulodesis – A pilot study of a novel minimally invasive surgical and medical approach for closure of perianal fistulae. <i>World Journal of Gastrointestinal Surgery</i> , 2021, 13, 187-197.	0.8	1
29	Diet and Inflammatory Bowel Disease: What Quality Standards Should Be Applied in Clinical and Laboratory Studies?. <i>Molecular Nutrition and Food Research</i> , 2021, 65, e2000514.	1.5	4
30	Higher educational level in patients with eosinophilic esophagitis: a comparative analysis. <i>Ecological Management and Restoration</i> , 2021, 34, .	0.2	1
31	Nutrition – or Lack Thereof – As a Source of Gut Inflammation: Evidence from Basic Science and Clinical Studies. <i>Molecular Nutrition and Food Research</i> , 2021, 65, e2001086.	1.5	1
32	A single nucleotide polymorphism in the gene for GPR183 increases its surface expression on blood lymphocytes of patients with inflammatory bowel disease. <i>British Journal of Pharmacology</i> , 2021, 178, 3157-3175.	2.7	9
33	Allogeneic expanded adipose-derived mesenchymal stem cell therapy for perianal fistulas in Crohn's disease: A case series. <i>Colorectal Disease</i> , 2021, 23, 1444-1450.	0.7	19
34	Combination of Vedolizumab With Tacrolimus Is More Efficient Than Vedolizumab Alone in the Treatment of Experimental Colitis. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1986-1998.	0.9	4
35	Selecting End Points for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT Consensus From the IOIBD. <i>Gastroenterology</i> , 2021, 160, 1452-1460.e21.	0.6	68
36	Type D personality is associated with depressive symptoms and clinical activity in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 53-67.	1.9	16

#	ARTICLE	IF	CITATIONS
37	Macrophages Compensate for Loss of Protein Tyrosine Phosphatase N2 in Dendritic Cells to Protect from Elevated Colitis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6820.	1.8	3
38	Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. <i>Lancet, The</i> , 2021, 397, 2372-2384.	6.3	194
39	Evaluating key characteristics of ideal colorectal cancer screening modalities: the microsimulation approach. <i>Gastrointestinal Endoscopy</i> , 2021, 94, 379-390.e7.	0.5	12
40	Commensal Clostridiales strains mediate effective anti-cancer immune response against solid tumors. <i>Cell Host and Microbe</i> , 2021, 29, 1573-1588.e7.	5.1	71
41	The impact of colectomy on the course of extraintestinal manifestations in Swiss inflammatory bowel disease cohort study patients. <i>United European Gastroenterology Journal</i> , 2021, 9, 773-780.	1.6	4
42	Modulation of the Mucosa-Associated Microbiome Linked to the PTPN2 Risk Gene in Patients with Primary Sclerosing Cholangitis and Ulcerative Colitis. <i>Microorganisms</i> , 2021, 9, 1752.	1.6	6
43	Extraintestinal Manifestations of Inflammatory Bowel Disease: Current Concepts, Treatment, and Implications for Disease Management. <i>Gastroenterology</i> , 2021, 161, 1118-1132.	0.6	267
44	Systemic Jak1 activation provokes hepatic inflammation and imbalanced FGF23 production and cleavage. <i>FASEB Journal</i> , 2021, 35, e21302.	0.2	13
45	Fatigue in inflammatory bowel disease and its impact on daily activities. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 138-149.	1.9	25
46	Clinical Relevance of Anti-TNF Antibody Trough Levels and Anti-Drug Antibodies in Treating Inflammatory Bowel Disease Patients. <i>Inflammatory Intestinal Diseases</i> , 2021, 6, 1-10.	0.8	15
47	Possible Adverse Effects of Food Additive E171 (Titanium Dioxide) Related to Particle Specific Human Toxicity, Including the Immune System. <i>International Journal of Molecular Sciences</i> , 2021, 22, 207.	1.8	47
48	MMP9 expression in intestinal fistula from patients with fistulizing CD and from human xenograft mouse model. <i>Tissue Barriers</i> , 2021, , 1994350.	1.6	1
49	OMO-3â€¦Safety analysis of filgotinib for ulcerative colitis: Phase 2b/3 selection study and long-term extension results. , 2021, , .		0
50	Genotype-phenotype associations of polymorphisms within the gene locus of NOD-like receptor pyrin domain containing 3 in Swiss inflammatory bowel disease patients. <i>BMC Gastroenterology</i> , 2021, 21, 310.	0.8	0
51	No Need to Scope? Monitoring of Treatment Response in IBD Patients by Transabdominal Ultrasound. <i>Journal of Crohn's and Colitis</i> , 2021, , .	0.6	0
52	Therapeutic Drug Monitoring to Guide Clinical Decision Making in Inflammatory Bowel Disease Patients with Loss of Response to Anti-TNF: A Delphi Technique-Based Consensus. <i>Digestion</i> , 2020, 101, 683-691.	1.2	12
53	Association of Alterations in Intestinal Microbiota With Impaired Psychological Function in Patients With Inflammatory Bowel Diseases in Remission. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2019-2029.e11.	2.4	64
54	Lower Risk of B1-to-pB3-Stage Migration in Crohnâ€™s Disease Upon Immunosuppressive and Anti-TNF Treatment in the Swiss IBD Cohort Study. <i>Digestive Diseases and Sciences</i> , 2020, 65, 2654-2663.	1.1	4

#	ARTICLE	IF	CITATIONS
55	Disease Progression and Outcomes of Pregnancies in Women With Eosinophilic Esophagitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2456-2462.	2.4	2
56	Efficacy of JAK inhibitors in Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S746-S754.	0.6	49
57	European society of neurogastroenterology and motility guidelines on functional constipation in adults. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13762.	1.6	110
58	Retrospective Analysis of Treatment and Complications of Immune Checkpoint Inhibitor-Associated Colitis: Histological Ulcerations as Potential Predictor for a Steroid-Refractory Disease Course. <i>Inflammatory Intestinal Diseases</i> , 2020, 5, 109-116.	0.8	17
59	Impact of obesity on disease activity and disease outcome in inflammatory bowel disease: Results from the Swiss inflammatory bowel disease cohort. <i>United European Gastroenterology Journal</i> , 2020, 8, 1196-1207.	1.6	24
60	Reconsidering the "protective" hypothesis of <i>Helicobacter pylori</i> infection in eosinophilic esophagitis. <i>Annals of the New York Academy of Sciences</i> , 2020, 1481, 59-71.	1.8	12
61	Responses to the Letter to the Editor by Bruscianno et al.. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13981.	1.6	1
62	Protein Tyrosine Phosphatase Non-Receptor Type 2 Function in Dendritic Cells Is Crucial to Maintain Tissue Tolerance. <i>Frontiers in Immunology</i> , 2020, 11, 1856.	2.2	14
63	Genetic risk factors predict disease progression in Crohn's disease patients of the Swiss inflammatory bowel disease cohort. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482095925.	1.4	7
64	The Influence of Breastfeeding, Cesarean Section, Pet Animals, and Urbanization on the Development of Inflammatory Bowel Disease: Data from the Swiss IBD Cohort Study. <i>Inflammatory Intestinal Diseases</i> , 2020, 5, 170-179.	0.8	3
65	A Multicentre, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of the S1P Receptor Agonist KRP203 in Patients with Moderately Active Refractory Ulcerative Colitis. <i>Inflammatory Intestinal Diseases</i> , 2020, 5, 180-190.	0.8	26
66	Efficacy and safety of methotrexate in the management of inflammatory bowel disease: A systematic review and meta-analysis of randomized, controlled trials. <i>EClinicalMedicine</i> , 2020, 20, 100271.	3.2	23
67	Treatment Algorithms for Crohn's Disease. <i>Digestion</i> , 2020, 101, 43-57.	1.2	47
68	Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease. <i>Gastroenterology</i> , 2020, 159, 139-147.	0.6	126
69	Genome-Scale CRISPR Screening in Human Intestinal Organoids Identifies Drivers of TGF- β Resistance. <i>Cell Stem Cell</i> , 2020, 26, 431-440.e8.	5.2	103
70	Effect of distance to specialist care for the diagnosis and disease outcome of inflammatory bowel disease in the Swiss inflammatory bowel disease cohort study. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628481989521.	1.4	2
71	Dietary Guidance From the International Organization for the Study of Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1381-1392.	2.4	161
72	Management of the Elderly Inflammatory Bowel Disease Patient. <i>Digestion</i> , 2020, 101, 105-119.	1.2	27

#	ARTICLE	IF	CITATIONS
73	Vaccination in Patients with Inflammatory Bowel Diseases. <i>Digestion</i> , 2020, 101, 58-68.	1.2	29
74	Improved treatment outcome and lower skin toxicity with intensity-modulated radiotherapy vs. 3D conventional radiotherapy in anal cancer. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 356-367.	1.0	8
75	Rapid expansion of Treg cells protects from collateral colitis following a viral trigger. <i>Nature Communications</i> , 2020, 11, 1522.	5.8	18
76	Activation of pH-Sensing Receptor OGR1 (GPR68) Induces ER Stress Via the IRE1 α /JNK Pathway in an Intestinal Epithelial Cell Model. <i>Scientific Reports</i> , 2020, 10, 1438.	1.6	32
77	Long noncoding RNA H19X is a key mediator of TGF- β -driven fibrosis. <i>Journal of Clinical Investigation</i> , 2020, 130, 4888-4905.	3.9	52
78	Medikamentöse Therapie der Colitis ulcerosa und Pouchitis. , 2020, , 285-303.		2
79	Inflammatory bowel disease in sub-Saharan Africa: a protocol of a prospective registry with a nested case-control study. <i>BMJ Open</i> , 2020, 10, e039456.	0.8	1
80	Klassifikationen, Indizes, Aktivitätsbeurteilung. , 2020, , 117-136.		0
81	Klinik der Colitis ulcerosa und Pouchitis. , 2020, , 87-94.		0
82	Mechanism-Based Treatment Strategies for IBD: Cytokines, Cell Adhesion Molecules, JAK Inhibitors, Gut Flora, and More. <i>Inflammatory Intestinal Diseases</i> , 2019, 4, 79-96.	0.8	53
83	A multicentre prospective cohort study assessing the effectiveness of budesonide MMX [®] (Cortiment [®] MMX [®]) for active, mild-to-moderate ulcerative colitis. <i>United European Gastroenterology Journal</i> , 2019, 7, 1171-1182.	1.6	9
84	Recurrent Fever and Failure to Thrive in an 11-Year-Old Boy. <i>Case Reports in Gastroenterology</i> , 2019, 13, 350-356.	0.3	0
85	Uveitis manifestations in patients of the Swiss Inflammatory Bowel Disease Cohort Study. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481986514.	1.4	20
86	Loss of PTPN22 abrogates the beneficial effect of cohousing-mediated fecal microbiota transfer in murine colitis. <i>Mucosal Immunology</i> , 2019, 12, 1336-1347.	2.7	21
87	Microbial network disturbances in relapsing refractory Crohn's disease. <i>Nature Medicine</i> , 2019, 25, 323-336.	15.2	277
88	Cohort Profile Update: The Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS). <i>International Journal of Epidemiology</i> , 2019, 48, 385-386f.	0.9	26
89	Occurrence of skin manifestations in patients of the Swiss Inflammatory Bowel Disease Cohort Study. <i>PLoS ONE</i> , 2019, 14, e0210436.	1.1	26
90	Iron Prevents Hypoxia-Associated Inflammation Through the Regulation of Nuclear Factor- κ B in the Intestinal Epithelium. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2019, 7, 339-355.	2.3	9

#	ARTICLE	IF	CITATIONS
91	Elevated oxysterol levels in human and mouse livers reflect nonalcoholic steatohepatitis. <i>Journal of Lipid Research</i> , 2019, 60, 1270-1283.	2.0	37
92	Tumor necrosis factor stimulates fibroblast growth factor 23 levels in chronic kidney disease and non-renal inflammation. <i>Kidney International</i> , 2019, 96, 890-905.	2.6	56
93	Systematic Analysis of the Impact of Diagnostic Delay on Bowel Damage in Paediatric Versus Adult Onset Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1334-1342.	0.6	38
94	The appearance of joint manifestations in the Swiss inflammatory bowel disease cohort. <i>PLoS ONE</i> , 2019, 14, e0211554.	1.1	15
95	Association of IBD specific treatment and prevalence of pain in the Swiss IBD cohort study. <i>PLoS ONE</i> , 2019, 14, e0215738.	1.1	5
96	Early Initiation of Anti-TNF is Associated with Favourable Long-term Outcome in Crohn's Disease: 10-Year-Follow-up Data from the Swiss IBD Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1292-1301.	0.6	37
97	The Evolution of Health Care Utilisation and Costs for Inflammatory Bowel Disease Over Ten Years. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 744-754.	0.6	38
98	Vegetarian or gluten-free diets in patients with inflammatory bowel disease are associated with lower psychological well-being and a different gut microbiota, but no beneficial effects on the course of the disease. <i>United European Gastroenterology Journal</i> , 2019, 7, 767-781.	1.6	67
99	The impact of the rs8005161 polymorphism on G protein-coupled receptor GPR65 (TDAG8) pH-associated activation in intestinal inflammation. <i>BMC Gastroenterology</i> , 2019, 19, 2.	0.8	24
100	Differences in Outcomes Reported by Patients With Inflammatory Bowel Diseases vs Their Health Care Professionals. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2050-2059.e1.	2.4	8
101	Efficacy of Endoscopic Dilatation of Gastroduodenal Crohn's Disease Strictures: A Systematic Review and Meta-Analysis of Individual Patient Data. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2514-2522.e8.	2.4	31
102	The long and winding road: from genetic risk factors to the understanding of disease-pathogenesis in Crohn's disease. <i>Genes and Immunity</i> , 2019, 20, 607-608.	2.2	3
103	Actual Anti-TNF Trough Levels Relate to Serum IL-10 in Drug-Responding Patients With Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1357-1366.	0.9	5
104	Efficacy and Safety of Abilumab in a Randomized, Placebo-Controlled Trial for Moderate-to-Severe Ulcerative Colitis. <i>Gastroenterology</i> , 2019, 156, 946-957.e18.	0.6	66
105	The EB12-oxysterol axis promotes the development of intestinal lymphoid structures and colitis. <i>Mucosal Immunology</i> , 2019, 12, 733-745.	2.7	40
106	Can the CalproQuest predict a positive Calprotectin test? A prospective diagnostic study. <i>PLoS ONE</i> , 2019, 14, e0224961.	1.1	3
107	Lack of the pH-sensing Receptor TDAG8 [GPR65] in Macrophages Plays a Detrimental Role in Murine Models of Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 245-258.	0.6	39
108	Transplantation of Human Intestine Into the Mouse: A Novel Platform for Study of Inflammatory Enterocutaneous Fistulas. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 798-806.	0.6	13

#	ARTICLE	IF	CITATIONS
109	Administration of the Hyper-immune Bovine Colostrum Extract IMM-124E Ameliorates Experimental Murine Colitis. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 785-797.	0.6	19
110	Integrin serves as a novel serum tumor marker for colorectal carcinoma. <i>International Journal of Cancer</i> , 2019, 145, 678-685.	2.3	42
111	Malignancies in Inflammatory Bowel Disease: Frequency, Incidence and Risk Factors—Results from the Swiss IBD Cohort Study. <i>American Journal of Gastroenterology</i> , 2019, 114, 116-126.	0.2	39
112	Feasibility of an 8-item questionnaire for early diagnosis of inflammatory bowel disease in primary care. <i>Journal of Evaluation in Clinical Practice</i> , 2019, 25, 155-162.	0.9	5
113	Succinate receptor mediates intestinal inflammation and fibrosis. <i>Mucosal Immunology</i> , 2019, 12, 178-187.	2.7	122
114	Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn's disease (ANDANTE I and II). <i>Gut</i> , 2019, 68, 40-48.	6.1	132
115	Protein tyrosine phosphatase non-receptor type 22 modulates colitis in a microbiota-dependent manner. <i>Journal of Clinical Investigation</i> , 2019, 129, 2527-2541.	3.9	15
116	Low serum zinc levels predict presence of depression symptoms, but not overall disease outcome, regardless of ATG16L1 genotype in Crohn's disease patients. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 1756283X1875771.	1.4	5
117	The Relevance of Vitamin and Iron Deficiency in Patients with Inflammatory Bowel Diseases in Patients of the Swiss IBD Cohort. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1768-1779.	0.9	32
118	Colectomy Rates in Ulcerative Colitis are Low and Decreasing: 10-year Follow-up Data From the Swiss IBD Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 811-818.	0.6	88
119	Clinical manifestations, pathophysiology, treatment and outcome of inflammatory bowel diseases in older people. <i>Maturitas</i> , 2018, 110, 71-78.	1.0	25
120	PTPN2 Regulates Inflammasome Activation and Controls Onset of Intestinal Inflammation and Colon Cancer. <i>Cell Reports</i> , 2018, 22, 1835-1848.	2.9	80
121	Frequency and type of drug-related side effects necessitating treatment discontinuation in the Swiss Inflammatory Bowel Disease Cohort. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 612-620.	0.8	30
122	The Proton-activated Receptor GPR4 Modulates Intestinal Inflammation. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 355-368.	0.6	55
123	Expression Patterns of TNF α , MAdCAM1, and STAT3 in Intestinal and Skin Manifestations of Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 347-354.	0.6	44
124	Identification of Endpoints for Development of Antifibrosis Drugs for Treatment of Crohn's Disease. <i>Gastroenterology</i> , 2018, 155, 76-87.	0.6	34
125	Development of an index to define overall disease severity in IBD. <i>Gut</i> , 2018, 67, 244-254.	6.1	108
126	Alicaforsen, an Antisense Inhibitor of Intercellular Adhesion Molecule-1, in the Treatment for Left-Sided Ulcerative Colitis and Ulcerative Proctitis. <i>Digestive Diseases</i> , 2018, 36, 123-129.	0.8	14

#	ARTICLE	IF	CITATIONS
127	Celiac Disease is Misdiagnosed Based on Serology Only in a Substantial Proportion of Patients. <i>Journal of Clinical Gastroenterology</i> , 2018, 52, 25-29.	1.1	9
128	The Vampire Study: Significant elevation of faecal calprotectin in healthy volunteers after 300â€‰ml blood ingestion mimicking upper gastrointestinal bleeding. <i>United European Gastroenterology Journal</i> , 2018, 6, 1007-1014.	1.6	14
129	Challenges of Translation of Anti-Fibrotic Therapies into Clinical Practice in IBD. , 2018, , 295-305.		1
130	Clinicopathological and Molecular Specificities of Inflammatory Bowel Diseaseâ€“Related Colorectal Neoplastic Lesions: The Role of Inflammation. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1486-1498.	0.6	18
131	Growth of Epithelial Organoids in a Defined Hydrogel. <i>Advanced Materials</i> , 2018, 30, e1801621.	11.1	200
132	Memory B Cells Activate Brain-Homing, Autoreactive CD4+ T Cells in Multiple Sclerosis. <i>Cell</i> , 2018, 175, 85-100.e23.	13.5	350
133	Intestinal Activation of pH-Sensing Receptor OGR1 [GPR68] Contributes to Fibrogenesis. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1348-1358.	0.6	29
134	BCL2 Regulates Differentiation of Intestinal Fibroblasts. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1953-1966.	0.9	17
135	The presence of genetic risk variants within PTPN2 and PTPN22 is associated with intestinal microbiota alterations in Swiss IBD cohort patients. <i>PLoS ONE</i> , 2018, 13, e0199664.	1.1	35
136	Vagus Nerve as Modulator of the Brainâ€“Gut Axis in Psychiatric and Inflammatory Disorders. <i>Frontiers in Psychiatry</i> , 2018, 9, 44.	1.3	564
137	Expression of Programmed Death-Ligand 1 by Human Colonic CD90+ Stromal Cells Differs Between Ulcerative Colitis and Crohnâ€™s Disease and Determines Their Capacity to Suppress Th1 Cells. <i>Frontiers in Immunology</i> , 2018, 9, 1125.	2.2	52
138	Upper Gastrointestinal Tract Involvement in Crohnâ€™s Disease: Frequency, Risk Factors, and Disease Course. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1399-1409.	0.6	40
139	Rectal Insulin Instillation Inhibits Inflammation and Tumor Development in Chemically Induced Colitis. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1459-1474.	0.6	6
140	Serum anti-glycan-antibodies in relatives of patients with inflammatory bowel disease. <i>PLoS ONE</i> , 2018, 13, e0194222.	1.1	4
141	Gp96 deficiency affects TLR4 functionality and impairs ERK and p38 phosphorylation. <i>PLoS ONE</i> , 2018, 13, e0193003.	1.1	7
142	New insights into the pathophysiology of inflammatory bowel disease: microbiota, epigenetics and common signalling pathways. <i>Swiss Medical Weekly</i> , 2018, 148, w14599.	0.8	27
143	Inflammatory Bowel Disease in Travelers. <i>Gastroenterology and Hepatology</i> , 2018, 14, 377-379.	0.2	1
144	Cellular and Molecular Mediators of Intestinal Fibrosis. <i>Journal of Crohn's and Colitis</i> , 2017, 11, j.crohns.2014.09.008.	0.6	99

#	ARTICLE	IF	CITATIONS
145	A Randomised, Double-blind, Placebo-controlled Trial of <i>Trichuris suis</i> ova in Active Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2017, 11, jw184.	0.6	54
146	Titanium dioxide nanoparticles exacerbate DSS-induced colitis: role of the NLRP3 inflammasome. <i>Gut</i> , 2017, 66, 1216-1224.	6.1	223
147	Systematic Evaluation of Diagnostic Delay in Pediatric Inflammatory Bowel Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2017, 64, 245-247.	0.9	20
148	Protocol for a prospective, controlled, observational study to evaluate the influence of hypoxia on healthy volunteers and patients with inflammatory bowel disease: the Altitude IBD Study. <i>BMJ Open</i> , 2017, 7, e013477.	0.8	7
149	Anti-Cytokine Strategies beyond Anti-Tumour Necrosis Factor- α Therapy: Pathophysiology and Clinical Implications. <i>Digestive Diseases</i> , 2017, 35, 5-12.	0.8	10
150	Immune Cells: Monocytes and Macrophages. , 2017, , 119-122.		2
151	Resolution of inflammation in inflammatory bowel disease. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 521-530.	3.7	51
152	Anthocyanins Prevent Colorectal Cancer Development in a Mouse Model. <i>Digestion</i> , 2017, 95, 275-280.	1.2	56
153	Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1174-1181.	0.9	72
154	Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management. <i>American Journal of Hematology</i> , 2017, 92, 1068-1078.	2.0	290
155	The perspective of celiac disease patients on emerging treatment options and non-celiac gluten sensitivity. <i>Digestive and Liver Disease</i> , 2017, 49, 268-272.	0.4	3
156	The Efficacy and Safety of Golimumab as Third- or Fourth-Line Anti-TNF Therapy in Patients with Refractory Crohn's Disease: A Case Series. <i>Inflammatory Intestinal Diseases</i> , 2017, 2, 131-138.	0.8	13
157	The Impact of Cold Spells on the Incidence of Infectious Gastroenteritis and Relapse Rates of Inflammatory Bowel Disease: A Retrospective Controlled Observational Study. <i>Inflammatory Intestinal Diseases</i> , 2017, 2, 124-130.	0.8	8
158	Gastroresistant oral peptide for fluorescence imaging of colonic inflammation. <i>Journal of Controlled Release</i> , 2017, 262, 118-126.	4.8	5
159	Autologous stem-cell transplantation in treatment-refractory Crohn's disease: an analysis of pooled data from the ASTIC trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 399-406.	3.7	70
160	Hypoxia ameliorates intestinal inflammation through NLRP3/mTOR downregulation and autophagy activation. <i>Nature Communications</i> , 2017, 8, 98.	5.8	224
161	Prevalence and Determinants of Job Stress in Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 310-317.	0.9	5
162	PTPN22 regulates NLRP3-mediated IL1B secretion in an autophagy-dependent manner. <i>Autophagy</i> , 2017, 13, 1590-1601.	4.3	90

#	ARTICLE	IF	CITATIONS
163	Alicaforsen in the treatment of pouchitis. <i>Immunotherapy</i> , 2017, 9, 1143-1152.	1.0	10
164	Extraintestinal Manifestations of Pediatric Inflammatory Bowel Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2017, 65, 200-206.	0.9	89
165	Patients' views on fecal microbiota transplantation: an acceptable therapeutic option in inflammatory bowel disease?. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 322-330.	0.8	17
166	Effects of oral antibiotics and isotretinoin on the murine gut microbiota. <i>International Journal of Antimicrobial Agents</i> , 2017, 50, 342-351.	1.1	27
167	Fistulizing Crohn's Disease. <i>Clinical and Translational Gastroenterology</i> , 2017, 8, e106.	1.3	24
168	Widely differing screening and treatment practice for osteoporosis in patients with inflammatory bowel diseases in the Swiss IBD cohort study. <i>Medicine (United States)</i> , 2017, 96, e6788.	0.4	26
169	Prdx6 Deficiency Ameliorates DSS Colitis: Relevance of Compensatory Antioxidant Mechanisms. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 871-884.	0.6	35
170	3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 2: Surgical Management and Special Situations. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 135-149.	0.6	558
171	Mechanisms, Management, and Treatment of Fibrosis in Patients With Inflammatory Bowel Diseases. <i>Gastroenterology</i> , 2017, 152, 340-350.e6.	0.6	317
172	Preventive <i>Trichuris suis ova</i> (TSO) treatment protects immunocompetent rabbits from DSS colitis but may be detrimental under conditions of immunosuppression. <i>Scientific Reports</i> , 2017, 7, 16500.	1.6	17
173	Factors Promoting Development of Fibrosis in Crohn's Disease. <i>Frontiers in Medicine</i> , 2017, 4, 96.	1.2	24
174	Anthocyane, Heidelbeeren und Curcuma: Wirksame Therapeutika bei Darmentzündungen?. <i>Schweizerische Zeitschrift für GanzheitsMedizin</i> , 2017, 29, 137-140.	0.0	1
175	Large-Scale Integrative Analysis of Epigenetic Modifications Induced by Isotretinoin, Doxycycline and Metronidazole in Murine Colonic Intestinal Epithelial Cells. <i>Epigenomes</i> , 2017, 1, 24.	0.8	0
176	Making a Case for Case Reports: The ECCO-CONFER Viewpoint on Investigating Rare Events in a Medical World Reigned by Group-comparative Statistics. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 256-257.	0.6	6
177	Eribulin Does Not Prevent Epithelial-to-Mesenchymal Transition in HT-29 Intestinal Epithelial Cells. <i>Inflammatory Intestinal Diseases</i> , 2017, 2, 211-218.	0.8	1
178	The Management of Inflammatory Bowel Disease in Elderly: Current Evidence and Future Perspectives. <i>Inflammatory Intestinal Diseases</i> , 2017, 2, 189-199.	0.8	26
179	Risk factors for gallstones and kidney stones in a cohort of patients with inflammatory bowel diseases. <i>PLoS ONE</i> , 2017, 12, e0185193.	1.1	54
180	The Role of the Chaperone Grp94/Gp96 in the Intestinal Barrier and Innate Immune Functions. <i>Current Immunology Reviews</i> , 2017, 13, .	1.2	1

#	ARTICLE	IF	CITATIONS
181	The Innate Immune System: A Trigger for Many Chronic Inflammatory Intestinal Diseases. <i>Inflammatory Intestinal Diseases</i> , 2016, 1, 70-77.	0.8	13
182	Risk Factors for the Development of Fistulae and Stenoses in Crohn Disease Patients in the Swiss Inflammatory Bowel Disease Cohort. <i>Inflammatory Intestinal Diseases</i> , 2016, 1, 172-181.	0.8	10
183	Bilberry-Derived Anthocyanins Modulate Cytokine Expression in the Intestine of Patients with Ulcerative Colitis. <i>PLoS ONE</i> , 2016, 11, e0154817.	1.1	71
184	The Impact of Azathioprine-Associated Lymphopenia on the Onset of Opportunistic Infections in Patients with Inflammatory Bowel Disease. <i>PLoS ONE</i> , 2016, 11, e0155218.	1.1	31
185	Pain in IBD Patients: Very Frequent and Frequently Insufficiently Taken into Account. <i>PLoS ONE</i> , 2016, 11, e0156666.	1.1	104
186	Genotype-Phenotype Associations of the CD-Associated Single Nucleotide Polymorphism within the Gene Locus Encoding Protein Tyrosine Phosphatase Non-Receptor Type 22 in Patients of the Swiss IBD Cohort. <i>PLoS ONE</i> , 2016, 11, e0160215.	1.1	7
187	Decreased Fibrogenesis After Treatment with Pirfenidone in a Newly Developed Mouse Model of Intestinal Fibrosis. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 569-582.	0.9	40
188	Long-term changes of bacterial and viral compositions in the intestine of a recovered <i>Clostridium difficile</i> patient after fecal microbiota transplantation. <i>Journal of Physical Education and Sports Management</i> , 2016, 2, a000448.	0.5	50
189	High Altitude Journeys, Flights and Hypoxia: Any Role for Disease Flares in IBD Patients?. <i>Digestive Diseases</i> , 2016, 34, 78-83.	0.8	22
190	Serologic Anti-GP2 Antibodies Are Associated with Genetic Polymorphisms, Fibrostenosis, and Need for Surgical Resection in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 2648-2657.	0.9	25
191	Experts Opinion on the Practical Use of Azathioprine and 6-Mercaptopurine in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 2733-2747.	0.9	35
192	Risk factors for complications in patients with ulcerative colitis. <i>United European Gastroenterology Journal</i> , 2016, 4, 281-287.	1.6	13
193	The Clinical Relevance of the IBD-Associated Variation within the Risk Gene Locus Encoding Protein Tyrosine Phosphatase Non-Receptor Type 2 in Patients of the Swiss IBD Cohort. <i>Digestion</i> , 2016, 93, 182-192.	1.2	10
194	Hypoxia Positively Regulates the Expression of pH-Sensing G-Protein-Coupled Receptor OGR1 (GPR68). <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2016, 2, 796-810.	2.3	34
195	The Search for Causative Environmental Factors in Inflammatory Bowel Disease. <i>Digestive Diseases</i> , 2016, 34, 48-55.	0.8	35
196	Identification of oncogenic driver mutations by genome-wide CRISPR-Cas9 dropout screening. <i>BMC Genomics</i> , 2016, 17, 723.	1.2	31
197	Cell-specific Activation of the Nrf2 Antioxidant Pathway Increases Mucosal Inflammation in Acute but Not in Chronic Colitis. <i>Journal of Crohn's and Colitis</i> , 2016, 11, jjw172.	0.6	22
198	Doxycycline, metronidazole and isotretinoin: Do they modify microRNA/mRNA expression profiles and function in murine T-cells?. <i>Scientific Reports</i> , 2016, 6, 37082.	1.6	22

#	ARTICLE	IF	CITATIONS
199	Prediction of low bone mineral density in patients with inflammatory bowel diseases. United European Gastroenterology Journal, 2016, 4, 669-676.	1.6	21
200	Preface. Digestive Diseases, 2016, 34, I-I.	0.8	0
201	Deficiency of Protein Tyrosine Phosphatase Non-Receptor Type 2 in Intestinal Epithelial Cells Has No Appreciable Impact on Dextran Sulphate Sodium Colitis Severity But Promotes Wound Healing. Digestion, 2016, 93, 249-259.	1.2	11
202	Anti-MMP-9 Antibody. Inflammatory Bowel Diseases, 2016, 22, 2041-2057.	0.9	64
203	Effectiveness of budesonide MMX (Cortiment) for the treatment of mild-to-moderate active ulcerative colitis: study protocol for a prospective multicentre observational cohort study. BMJ Open Gastroenterology, 2016, 3, e000092.	1.1	7
204	Celiac disease diagnosis still significantly delayed – Doctor's but not patients' delay responsive for the increased total delay in women. Digestive and Liver Disease, 2016, 48, 1148-1154.	0.4	30
205	The two sides of the coin: Similarities and differences in the pathomechanisms of fistulas and stricture formations in irritable bowel disease. United European Gastroenterology Journal, 2016, 4, 506-514.	1.6	16
206	Symptoms of Depression and Anxiety Are Independently Associated With Clinical Recurrence of Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2016, 14, 829-835.e1.	2.4	260
207	Alicaforsen, an antisense inhibitor of ICAM-1, as treatment for chronic refractory pouchitis after proctocolectomy: A case series. United European Gastroenterology Journal, 2016, 4, 97-104.	1.6	44
208	Editorial: how to interpret risks and prediction of complications in Crohn's disease – can our patients interpret them?. Alimentary Pharmacology and Therapeutics, 2016, 43, 651-652.	1.9	1
209	Association of extraintestinal manifestations and anaemia with disease outcomes in patients with inflammatory bowel disease. Scandinavian Journal of Gastroenterology, 2016, 51, 848-854.	0.6	39
210	Gut Bacterial DNA Translocation is an Independent Risk Factor of Flare at Short Term in Patients With Crohn's Disease. American Journal of Gastroenterology, 2016, 111, 529-540.	0.2	34
211	Results of the Fifth Scientific Workshop of the ECCO [II]: Clinical Aspects of Perianal Fistulising Crohn's Disease – the Unmet Needs. Journal of Crohn's and Colitis, 2016, 10, 758-765.	0.6	49
212	Monitoring colonoscopy withdrawal time significantly improves the adenoma detection rate and the performance of endoscopists. Endoscopy, 2016, 48, 256-262.	1.0	45
213	Results of the Fifth Scientific Workshop of the ECCO (II): Pathophysiology of Perianal Fistulizing Disease. Journal of Crohn's and Colitis, 2016, 10, 377-386.	0.6	92
214	NLRP3 tyrosine phosphorylation is controlled by protein tyrosine phosphatase PTPN22. Journal of Clinical Investigation, 2016, 126, 1783-1800.	3.9	171
215	Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma. PLoS ONE, 2016, 11, e0147682.	1.1	32
216	Information Needs and Concerns of Patients with Inflammatory Bowel Disease: What Can We Learn from Participants in a Bilingual Clinical Cohort?. PLoS ONE, 2016, 11, e0150620.	1.1	35

#	ARTICLE	IF	CITATIONS
217	Protein tyrosine phosphatase non-receptor type 2 and inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2016, 22, 1034.	1.4	28
218	Integrating Imaging into Clinical Practice in Inflammatory Bowel Disease. <i>Digestive Diseases</i> , 2015, 33, 37-43.	0.8	3
219	G Protein-coupled pH-sensing Receptor OGR1 Is a Regulator of Intestinal Inflammation. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1.	0.9	63
220	Anti-inflammatory Function of High-Density Lipoproteins via Autophagy of Î²B Kinase. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2015, 1, 171-187.e1.	2.3	33
221	Patients'™ perceptions on the impact of coffee consumption in inflammatory bowel disease: friend or foe? " a patient survey. <i>Nutrition Journal</i> , 2015, 14, 78.	1.5	14
222	Chronological Order of Appearance of Extraintestinal Manifestations Relative to the Time of IBD Diagnosis in the Swiss Inflammatory Bowel Disease Cohort. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1794-1800.	0.9	175
223	Impact of the early use of immunomodulators or TNF antagonists on bowel damage and surgery in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 977-989.	1.9	91
224	Prevalence and Risk Factors for Therapy Escalation in Ulcerative Colitis in the Swiss IBD Cohort Study. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1.	0.9	11
225	Systematic analysis of factors associated with progression and regression of ulcerative colitis in 918 patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 540-548.	1.9	23
226	Extraintestinal Manifestations of Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1982-1992.	0.9	565
227	Autologous Hematopoietic Stem Cell Transplantation for Refractory Crohn Disease. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 2524.	3.8	136
228	High Rates of Smoking Especially in Female Crohn's™ Disease Patients and Low Use of Supportive Measures to Achieve Smoking Cessation" Data from the Swiss IBD Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 819-829.	0.6	52
229	VALidation of an 8-item-questionnaire predictive for a positive calprotectin tEst and Real-life implemenTation in primary care to reduce diagnostic delay in inflammatory bowel disease (ALERT): protocol for a prospective diagnostic study. <i>BMJ Open</i> , 2015, 5, e007306-e007306.	0.8	8
230	Serum REG3alpha and C-Reactive Protein Levels in Crohn's Disease Patients Undergoing Immunoablation and Autologous Hemopoietic Stem Cell Transplantation in the ASTIC Trial. <i>Digestion</i> , 2015, 92, 83-89.	1.2	0
231	New Onset, Aggravation and Recurrence of Crohn's Disease upon Treatment with Three Different Tumor Necrosis Factor Inhibitors. <i>Case Reports in Gastroenterology</i> , 2015, 9, 106-112.	0.3	7
232	Pushing the Pedal to the Metal: Should We Accelerate Infliximab Therapy for Patients With Severe Ulcerative Colitis?. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 336-338.	2.4	34
233	Species-specific engagement of human nucleotide oligomerization domain 2 (NOD)2 and Toll-like receptor (TLR) signalling upon intracellular bacterial infection: role of Crohn's associated NOD2 gene variants. <i>Clinical and Experimental Immunology</i> , 2015, 179, 426-434.	1.1	18
234	The intestinal microbiota: its role in health and disease. <i>European Journal of Pediatrics</i> , 2015, 174, 151-167.	1.3	144

#	ARTICLE	IF	CITATIONS
235	Oral administration of dextran sodium sulphate induces a caecum-localized colitis in rabbits. <i>International Journal of Experimental Pathology</i> , 2015, 96, 151-162.	0.6	11
236	Helminth therapy for organic diseases?. <i>Translational Research</i> , 2015, 166, 586-601.	2.2	11
237	Cogan's Syndrome in Patients With Inflammatory Bowel Disease – A Case Series. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 886-890.	0.6	22
238	Clinical Utility of Biomarkers in IBD. <i>Current Gastroenterology Reports</i> , 2015, 17, 26.	1.1	23
239	828 Prolonged Regression of Ileocolonic Crohn's Disease Following Autologous Haemopoietic Stem Cell Transplantation: Presentation on Behalf of the Astic Trialists. <i>Gastroenterology</i> , 2015, 148, S-163.	0.6	0
240	Hallmarks of epithelial to mesenchymal transition are detectable in Crohn's disease associated intestinal fibrosis. <i>Clinical and Translational Medicine</i> , 2015, 4, 1.	1.7	108
241	White-Light or Narrow-Band Imaging Colonoscopy in Surveillance of Ulcerative Colitis: A Prospective Multicenter Study. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1776-1781.e1.	2.4	44
242	Exposome in IBD. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 400-408.	0.9	100
243	<i>Helicobacter pylori</i> -specific Protection Against Inflammatory Bowel Disease Requires the NLRP3 Inflammasome and IL-18. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 854-861.	0.9	65
244	Role of Protein Tyrosine Phosphatases in Regulating the Immune System. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 645-655.	0.9	32
245	Increased lymphocyte apoptosis in mouse models of colitis upon ABT-737 treatment is dependent upon BIM expression. <i>Clinical and Experimental Immunology</i> , 2015, 181, 343-356.	1.1	19
246	The pH-sensing receptor OGR1 improves barrier function of epithelial cells and inhibits migration in an acidic environment. <i>American Journal of Physiology - Renal Physiology</i> , 2015, 309, G475-G490.	1.6	33
247	Assessment of Inflammatory Bowel Disease Patient's Needs and Problems from a Nursing Perspective. <i>Digestion</i> , 2015, 91, 128-141.	1.2	11
248	Severe Sweet's Syndrome with Elevated Cutaneous Interleukin-1 β after Azathioprine Exposure: Case Report and Review of the Literature. <i>Dermatology</i> , 2015, 230, 293-298.	0.9	32
249	Editorial: is thalidomide a good option for patients with refractory Crohn's disease?. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 785-786.	1.9	2
250	Deviations in human gut microbiota: a novel diagnostic test for determining dysbiosis in patients with IBS or IBD. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 71-83.	1.9	218
251	European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 945-965.	0.6	328
252	Where are we heading to in pharmacological IBD therapy?. <i>Pharmacological Research</i> , 2015, 100, 220-227.	3.1	36

#	ARTICLE	IF	CITATIONS
253	Donor Nucleotide-Binding Oligomerization-Containing Protein 2 (NOD2) Single Nucleotide Polymorphism 13 Is Associated with Septic Shock after Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1399-1404.	2.0	9
254	PTPN2 controls differentiation of CD4+ T cells and limits intestinal inflammation and intestinal dysbiosis. <i>Mucosal Immunology</i> , 2015, 8, 918-929.	2.7	93
255	The role and advances of immunomodulator therapy for inflammatory bowel disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 177-189.	1.4	27
256	Mutant HRAS as novel target for MEK and mTOR inhibitors. <i>Oncotarget</i> , 2015, 6, 42183-42196.	0.8	40
257	Targeting the RAS pathway by mitogen-activated protein kinase inhibitors. <i>Swiss Medical Weekly</i> , 2015, 145, w14207.	0.8	16
258	Biologics for Extraintestinal Manifestations of IBD. <i>Current Drug Targets</i> , 2014, 15, 1064-1073.	1.0	36
259	Hemoglobin and Hematocrit Levels in the Prediction of Complicated Crohn's Disease Behavior - A Cohort Study. <i>PLoS ONE</i> , 2014, 9, e104706.	1.1	25
260	Cell-wall deficient <i>L. monocytogenes</i> L-forms feature abrogated pathogenicity. <i>Frontiers in Cellular and Infection Microbiology</i> , 2014, 4, 60.	1.8	11
261	Analysis of TNF-antagonist switch over time and associated risk factors in the Swiss Inflammatory Bowel Disease Cohort. <i>Scandinavian Journal of Gastroenterology</i> , 2014, 49, 1207-1218.	0.6	8
262	Induction or Exacerbation of Psoriasis in Patients with Crohn's Disease under Treatment with Anti-TNF Antibodies. <i>Digestion</i> , 2014, 89, 209-215.	1.2	18
263	Aluminum enhances inflammation and decreases mucosal healing in experimental colitis in mice. <i>Mucosal Immunology</i> , 2014, 7, 589-601.	2.7	78
264	Bilberry-Derived Anthocyanins Prevent IFN- γ -Induced Pro-Inflammatory Signalling and Cytokine Secretion in Human THP-1 Monocytic Cells. <i>Digestion</i> , 2014, 90, 179-189.	1.2	33
265	New Therapeutic Avenues for Treatment of Fibrosis: Can We Learn from Other Diseases?. <i>Digestive Diseases</i> , 2014, 32, 39-49.	0.8	12
266	Probiotic <i>Escherichia coli</i> Nissle 1917 and Commensal <i>E. coli</i> K12 Differentially Affect the Inflammasome in Intestinal Epithelial Cells. <i>Digestion</i> , 2014, 89, 110-118.	1.2	34
267	Crohn's Disease: Loss of Tolerance or a Disorder of Autophagy?. <i>Digestive Diseases</i> , 2014, 32, 370-377.	0.8	23
268	Apoptotic enteropathy caused by antimetabolites and TNF- $\hat{\pm}$ antagonists. <i>Journal of Clinical Pathology</i> , 2014, 67, 582-586.	1.0	35
269	Downregulation of duodenal SLC transporters and activation of proinflammatory signaling constitute the early response to high altitude in humans. <i>American Journal of Physiology - Renal Physiology</i> , 2014, 307, G673-G688.	1.6	29
270	Patients' information-seeking activity is associated with treatment compliance in inflammatory bowel disease patients. <i>Scandinavian Journal of Gastroenterology</i> , 2014, 49, 662-673.	0.6	17

#	ARTICLE	IF	CITATIONS
271	A distinct pattern of disease-associated single nucleotide polymorphisms in IBD risk genes in a family with Crohn's disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 803-806.	0.8	2
272	Exogenous Heat Shock Protein gp96 Ameliorates CD4+CD62L+ T-Cell-mediated Transfer Colitis. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 1933-1941.	0.9	2
273	Smoking Cessation Alters Intestinal Microbiota. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 1496-1501.	0.9	142
274	Epithelial-to-mesenchymal transition in a fistula-associated anal adenocarcinoma in a patient with long-standing Crohn's disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 114-118.	0.8	36
275	Monitoring Disease Activity and Progression in Crohn's Disease. A Swiss Perspective on the IBD Ahead 'Optimised Monitoring' Recommendations. <i>Digestion</i> , 2014, 89, 299-309.	1.2	25
276	Risk Factors for Repetitive Ileocolic Resection in Patients with Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 1548-1554.	0.9	32
277	Transcriptional Analysis of Left-sided Colitis, Pancolitis, and Ulcerative Colitis-associated Dysplasia. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 2340-2352.	0.9	27
278	Results of the 4th scientific workshop of the ECCO (I): Pathophysiology of intestinal fibrosis in IBD. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1147-1165.	0.6	131
279	Coping is excellent in Swiss Children with inflammatory bowel disease: Results from the Swiss IBD cohort study. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 409-420.	0.6	15
280	Chronic ulcerative colitis and colorectal cancer. <i>Cancer Letters</i> , 2014, 345, 235-241.	3.2	280
281	Steroid Use in Crohn's Disease. <i>Drugs</i> , 2014, 74, 313-324.	4.9	10
282	The heart and the gut. <i>European Heart Journal</i> , 2014, 35, 426-430.	1.0	123
283	Addressing current treatment challenges in Crohn's disease in real life: A physician's survey. <i>Digestive and Liver Disease</i> , 2014, 46, 1066-1071.	0.4	4
284	Genetic susceptibility to increased bacterial translocation influences the response to biological therapy in patients with Crohn's disease. <i>Gut</i> , 2014, 63, 272-280.	6.1	62
285	Fistulising disease—a problem shared is a problem halved?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014, 11, 581-583.	8.2	2
286	Sphingomyelin and phosphatidylcholine contrarily affect the induction of apoptosis in intestinal epithelial cells. <i>Molecular Nutrition and Food Research</i> , 2014, 58, 782-798.	1.5	17
287	Autophagy Gene Atg16l1 Prevents Lethal T Cell Alloreactivity Mediated by Dendritic Cells. <i>Immunity</i> , 2014, 41, 579-591.	6.6	87
288	Topical therapy is underused in patients with ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 56-63.	0.6	52

#	ARTICLE	IF	CITATIONS
289	High altitude journeys and flights are associated with an increased risk of flares in inflammatory bowel disease patients. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 191-199.	0.6	37
290	The effectiveness and safety of rescue treatments in 108 patients with steroid-refractory ulcerative colitis with sequential rescue therapies in a subgroup of patients. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1427-1437.	0.6	31
291	Anemia in Inflammatory Bowel Disease: An Under-Estimated Problem?. <i>Frontiers in Medicine</i> , 2014, 1, 58.	1.2	33
292	Pathophysiology of fistula formation in Crohn's disease. <i>World Journal of Gastrointestinal Pathophysiology</i> , 2014, 5, 205.	0.5	93
293	Drug-induced Erythema Nodosum After the Administration of Certolizumab in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, E4-E6.	0.9	12
294	Recent Advances Using Immunomodulators for Inflammatory Bowel Disease. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 575-588.	1.0	37
295	Muramyl dipeptide responsive pathways in Crohn's disease: from NOD2 and beyond. <i>Cellular and Molecular Life Sciences</i> , 2013, 70, 3391-3404.	2.4	26
296	CYP3A4-Catalyzed Simvastatin Metabolism as a Non-Invasive Marker of Small Intestinal Health in Celiac Disease. <i>American Journal of Gastroenterology</i> , 2013, 108, 1344-1351.	0.2	36
297	Su1261 Expression of Interleukins 22 and 33, Matrix Metalloproteinases 9 and 13, Mast Cell Markers and Hypoxia-Inducible Factor 1 α in Crohn's Disease Associated Fistulae. <i>Gastroenterology</i> , 2013, 144, S-441-S-442.	0.6	3
298	Burrowing is a sensitive behavioural assay for monitoring general wellbeing during dextran sulfate sodium colitis in laboratory mice. <i>Laboratory Animals</i> , 2013, 47, 274-283.	0.5	50
299	Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 3: Special situations. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 1-33.	0.6	422
300	Magnetization transfer for the assessment of bowel fibrosis in patients with Crohn's disease: initial experience. <i>Magnetic Resonance Materials in Physics, Biology, and Medicine</i> , 2013, 26, 291-301.	1.1	79
301	Diagnostic Delay in Crohn's Disease Is Associated With a Complicated Disease Course and Increased Operation Rate. <i>American Journal of Gastroenterology</i> , 2013, 108, 1744-1753.	0.2	175
302	Concept for a rapid point-of-care calprotectin diagnostic test for diagnosis and disease activity monitoring in patients with inflammatory bowel disease: Expert clinical opinion. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 670-677.	0.6	41
303	Is There Still a Role for Thiopurines in Crohn's Disease?. <i>Gastroenterology</i> , 2013, 145, 714-716.	0.6	11
304	Bilberry ingestion improves disease activity in mild to moderate ulcerative colitis – An open pilot study. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 271-279.	0.6	106
305	The effects of vitamin A on cells of innate immunity in vitro. <i>Toxicology in Vitro</i> , 2013, 27, 1525-1532.	1.1	31
306	Identification of a SIRT1 Mutation in a Family with Type 1 Diabetes. <i>Cell Metabolism</i> , 2013, 17, 448-455.	7.2	103

#	ARTICLE	IF	CITATIONS
307	Loss of Protein Tyrosine Phosphatase Nonreceptor Type 22 Regulates Interferon- β -Induced Signaling in Human Monocytes. <i>Gastroenterology</i> , 2013, 144, 978-988.e10.	0.6	46
308	Imaging techniques for assessment of inflammatory bowel disease: Joint ECCO and ESGAR evidence-based consensus guidelines. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 556-585.	0.6	541
309	Low allopurinol doses are sufficient to optimize azathioprine therapy in inflammatory bowel disease patients with inadequate thiopurine metabolite concentrations. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 1521-1531.	0.8	35
310	Mast cells and the cyclooxygenase pathway mediate colonic afferent nerve sensitization in a murine colitis model. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2013, 174, 47-53.	1.4	1
311	Smoking Cessation Induces Profound Changes in the Composition of the Intestinal Microbiota in Humans. <i>PLoS ONE</i> , 2013, 8, e59260.	1.1	305
312	A Role for Tumor Necrosis Factor and Bacterial Antigens in the Pathogenesis of Crohn's Disease-Associated Fistulae. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 2878-2887.	0.9	27
313	Effects of Retinoids in Mouse Models of Colitis. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 2356-2365.	0.9	9
314	Periodontitis and Gingivitis in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 2768-2777.	0.9	102
315	The History and Philosophy of Inflammatory Bowel Disease. <i>Digestive Diseases</i> , 2013, 31, 270-277.	0.8	6
316	Penetrating or Stricturing Diseases are the Major Determinants of Time to First and Repeat Resection Surgery in Crohn's Disease. <i>Digestion</i> , 2013, 87, 212-221.	1.2	33
317	Hypoxia Induces the Expression of Transketolase-Like 1 in Human Colorectal Cancer. <i>Digestion</i> , 2013, 88, 182-192.	1.2	23
318	A New Heterotopic Transplant Animal Model of Intestinal Fibrosis. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 2302-2314.	0.9	22
319	Milk oligosaccharide sialyl(β 2,3)lactose activates intestinal CD11c ⁺ cells through TLR4. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 17444-17449.	3.3	89
320	Crohn's disease: small bowel motility impairment correlates with inflammatory-related markers C-reactive protein and calprotectin. <i>Neurogastroenterology and Motility</i> , 2013, 25, 467.	1.6	65
321	Analysis of the Intestinal Microbiome of a Recovered Clostridium difficile Patient after Fecal Transplantation. <i>Digestion</i> , 2013, 88, 243-251.	1.2	33
322	Impaired removal of CD8 ⁺ lymphocytes aggravates colitis in mice deficient for B cell lymphoma-2-interacting mediator of cell death (Bim). <i>Clinical and Experimental Immunology</i> , 2013, 173, 493-501.	1.1	5
323	Heat Waves, Incidence of Infectious Gastroenteritis, and Relapse Rates of Inflammatory Bowel Disease: A Retrospective Controlled Observational Study. <i>American Journal of Gastroenterology</i> , 2013, 108, 1480-1485.	0.2	31
324	Interleukin-13 and transforming growth factor β 2 synergise in the pathogenesis of human intestinal fistulae. <i>Gut</i> , 2013, 62, 63-72.	6.1	108

#	ARTICLE	IF	CITATIONS
325	Top-Down or Step-Up Treatment in Crohn's Disease?. <i>Digestive Diseases</i> , 2013, 31, 83-90.	0.8	48
326	A Shift From Oral to Intravenous Iron Supplementation Therapy Is Observed Over Time in a Large Swiss Cohort of Patients With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 840-846.	0.9	10
327	Use of thiopurines in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2013, 19, 1040.	1.4	32
328	Activation of Protein Tyrosine Phosphatase Non-Receptor Type 2 by Spermidine Exerts Anti-Inflammatory Effects in Human THP-1 Monocytes and in a Mouse Model of Acute Colitis. <i>PLoS ONE</i> , 2013, 8, e73703.	1.1	36
329	The Role for Dickkopf-Homolog-1 in the Pathogenesis of Crohn's Disease-Associated Fistulae. <i>PLoS ONE</i> , 2013, 8, e78882.	1.1	28
330	Protein Tyrosine Phosphatase Non-Receptor Type 22 Modulates NOD2-Induced Cytokine Release and Autophagy. <i>PLoS ONE</i> , 2013, 8, e72384.	1.1	38
331	Regulation of the Expression of Chaperone gp96 in Macrophages and Dendritic Cells. <i>PLoS ONE</i> , 2013, 8, e76350.	1.1	10
332	Review: New Anti-Cytokines for IBD: What is in the Pipeline?. <i>Current Drug Targets</i> , 2013, 14, 1405-1420.	1.0	19
333	Mucosal healing and deep remission: What does it mean?. <i>World Journal of Gastroenterology</i> , 2013, 19, 7552.	1.4	58
334	Inflammatory bowel disease pathogenesis. <i>Current Opinion in Gastroenterology</i> , 2012, 28, 301-309.	1.0	72
335	MIP-3 α Expression in Macrophages Is NOD Dependent. <i>Digestion</i> , 2012, 85, 192-201.	1.2	4
336	Role of biological therapy for inflammatory bowel disease in developing countries. <i>Gut</i> , 2012, 61, 706-712.	6.1	39
337	Downregulation of the Ubiquitin-Proteasome System in Normal Colonic Macrophages and Reinduction in Inflammatory Bowel Disease. <i>Digestion</i> , 2012, 86, 34-47.	1.2	18
338	Preface. <i>Digestion</i> , 2012, 86, IV-IV.	1.2	0
339	Dealing with Our 'In-Vironment': New Aspects of Inflammatory Bowel Disease Pathogenesis and Therapy. <i>Digestive Diseases</i> , 2012, 30, 1-1.	0.8	0
340	Environmental Factors and Their Impact on the Intestinal Microbiota: A Role for Human Disease?. <i>Digestive Diseases</i> , 2012, 30, 20-27.	0.8	10
341	Intensified Anti-TNF-Alpha Therapy and Bacterial-DNA Translocation in Patients With Mutated NOD2/ATG16L1-Combined Genotypes. <i>Inflammatory Bowel Diseases</i> , 2012, 18, S60.	0.9	0
342	Mo1976 Knock-out of BCL-2 Interacting Mediator of Cell Death (Bim) Aggravates Chronic DSS-Induced Colitis. <i>Gastroenterology</i> , 2012, 142, S-712.	0.6	0

#	ARTICLE	IF	CITATIONS
343	Therapy of Steroid-Resistant Inflammatory Bowel Disease. <i>Digestion</i> , 2012, 86, 11-15.	1.2	30
344	Beta-glucosidase 2 knockout mice with increased glucosylceramide show impaired liver regeneration. <i>Liver International</i> , 2012, 32, 1354-1362.	1.9	22
345	Association of genetic variation in the NR1H4 gene, encoding the nuclear bile acid receptor FXR, with inflammatory bowel disease. <i>BMC Research Notes</i> , 2012, 5, 461.	0.6	44
346	Pregnancy and Breastfeeding in Inflammatory Bowel Disease. <i>Digestion</i> , 2012, 86, 45-54.	1.2	21
347	Inflammatory Bowel Disease Cancer Risk, Detection and Surveillance. <i>Digestive Diseases</i> , 2012, 30, 48-54.	0.8	31
348	Intestinal Absorption and Vitamin Levels: Is a New Focus Needed?. <i>Digestive Diseases</i> , 2012, 30, 73-80.	0.8	24
349	Variants in Autophagy Genes Affect Susceptibility to Both Crohn's Disease and Helicobacter pylori Infection. <i>Gastroenterology</i> , 2012, 142, 1060-1063.	0.6	5
350	Results of the 2nd Scientific Workshop of the ECCO (III): Basic mechanisms of intestinal healing. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 373-375.	0.6	50
351	Mucosal Healing with Anti-TNF Antibodies. <i>Digestion</i> , 2012, 86, 16-22.	1.2	18
352	Topical Therapies in Inflammatory Bowel Disease. <i>Digestion</i> , 2012, 86, 36-44.	1.2	29
353	First-Line Therapies in Inflammatory Bowel Disease. <i>Digestion</i> , 2012, 86, 6-10.	1.2	40
354	Microparticles and Their Impact on Intestinal Immunity. <i>Digestive Diseases</i> , 2012, 30, 47-54.	0.8	29
355	Inflammatory Bowel Disease: Dysfunction of Autophagy?. <i>Digestive Diseases</i> , 2012, 30, 12-19.	0.8	65
356	Clinical Utility of Anti-Glycan Antibodies in Pediatric Crohn's Disease in Comparison with An Adult Cohort. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 1221-1231.	0.9	24
357	Systematic Assessment of Factors Influencing Preferences of Crohn's Disease Patients in Selecting an Anti-Tumor Necrosis Factor Agent (CHOOSE TNF TRIAL). <i>Inflammatory Bowel Diseases</i> , 2012, 18, 1523-1530.	0.9	59
358	Protein Tyrosine Phosphatase Nonreceptor Type 2 Regulates Autophagosome Formation in Human Intestinal Cells. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 1287-1302.	0.9	60
359	Crohn's disease-associated polymorphism within the PTPN2 gene affects muramyl-dipeptide-induced cytokine secretion and autophagy. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 900-912.	0.9	71
360	The role for protein tyrosine phosphatase nonreceptor type 2 in regulating autophagosome formation. <i>Annals of the New York Academy of Sciences</i> , 2012, 1257, 93-102.	1.8	11

#	ARTICLE	IF	CITATIONS
361	Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 496-505.	0.9	204
362	Fc Gamma Receptor CD64 Modulates the Inhibitory Activity of Infliximab. <i>PLoS ONE</i> , 2012, 7, e43361.	1.1	41
363	Transcription Factor NRF2 and Its Target Genes Are Differently Regulated in Acute and Chronic Colitis. <i>Gastroenterology</i> , 2011, 140, S-636.	0.6	0
364	Overexpression of Receptors for Insulin and Epidermal Growth Factor in Dysplastic Inflamed Colonic Mucosa Correlates With Increased Cancer Risk in Patients With Ulcerative Colitis. <i>Gastroenterology</i> , 2011, 140, S-350.	0.6	0
365	Protein tyrosine phosphatase N2 regulates TNF α -induced signalling and cytokine secretion in human intestinal epithelial cells. <i>Gut</i> , 2011, 60, 189-197.	6.1	72
366	Oxidative Stress and Deletion of Transketolase-Like (TKTL) 1 in Murine Experimental Colitis. <i>Gastroenterology</i> , 2011, 140, S-649.	0.6	0
367	Transforming Growth Factor Beta and Interleukin-13 Synergize in the Pathogenesis of Crohn's Disease Associated Intestinal Fistulae. <i>Gastroenterology</i> , 2011, 140, S-285.	0.6	0
368	The Lipids Sphingomyelin and Phosphatidylcholine Contrarily Affect the Induction of Apoptosis in Human Intestinal Epithelial Cells. <i>Gastroenterology</i> , 2011, 140, S-859-S-860.	0.6	0
369	Anti-Inflammatory Properties of High Density Lipoprotein (HDL) on Intestinal Epithelial Cells. <i>Gastroenterology</i> , 2011, 140, S-838.	0.6	0
370	Role of pH Receptors in Murine Experimental Colitis. <i>Gastroenterology</i> , 2011, 140, S-516.	0.6	0
371	A New Animal Model of Intestinal Fibrosis. <i>Gastroenterology</i> , 2011, 140, S-657.	0.6	0
372	Association between Cogan's syndrome and inflammatory bowel disease: A case series. <i>Journal of Crohn's and Colitis</i> , 2011, 5, 64-68.	0.6	22
373	Interaction between Susceptibility and Environment: Examples from the Digestive Tract. <i>Digestive Diseases</i> , 2011, 29, 136-143.	0.8	18
374	Protein Tyrosine Phosphatase Non-Receptor Type 2 is a Regulator of Autophagosome Function. <i>Gastroenterology</i> , 2011, 140, S-172.	0.6	0
375	Human Colonic Myofibroblasts Promote Expansion of CD4 ⁺ CD25 ^{high} Foxp3 ⁺ Regulatory T Cells. <i>Gastroenterology</i> , 2011, 140, 2019-2030.	0.6	59
376	Knock-Out of β -Glucosidase 2 Has No Influence on Dextran Sulfate Sodium-Induced Colitis. <i>Digestion</i> , 2011, 84, 156-167.	1.2	9
377	Loss of Heat Shock Protein gp96 Does Not Impair Toll Like Receptor Signaling In Vitro. <i>Gastroenterology</i> , 2011, 140, S-332.	0.6	0
378	Protein Tyrosine Phosphatase Non-Receptor Type 2 Regulates NLRP3 Inflammasome Activation. <i>Gastroenterology</i> , 2011, 140, S-633.	0.6	0

#	ARTICLE	IF	CITATIONS
379	Comparison of Protein Expression Profiles in Inflammatory Bowel Disease and Concomitant Cutaneous Manifestations on Tissue Microarrays. <i>Gastroenterology</i> , 2011, 140, S-427.	0.6	0
380	The Crohn's Disease Associated Variant of the Protein Tyrosine Phosphatase Non-Receptor Type 2 Gene Affects Cellular Responses to Invading <i>Listeria Monocytogenes</i> . <i>Gastroenterology</i> , 2011, 140, S-496.	0.6	0
381	Knock-out of BCL-2 Interacting Mediator of Cell Death (BIM) Decreases Apoptosis in Intestinal Epithelial Cells and Ameliorates Acute DSS Colitis. <i>Gastroenterology</i> , 2011, 140, S-648.	0.6	1
382	Systematic Assessment of Items Influencing Crohn's Disease Patient's Preferences in Selecting an Anti-TNF Agent (Choose TNF Trial). <i>Gastroenterology</i> , 2011, 140, S-593.	0.6	0
383	The Crohn's Disease Candidate Gene, Protein Tyrosine Phosphatase Non-Receptor Type 2, Regulates Muramyl-dipeptide-Induced NOD2-Dependent Effects in Human Monocytes and Fibroblasts. <i>Gastroenterology</i> , 2011, 140, S-487.	0.6	0
384	The FC Fragment of Infliximab Inhibits Its Activity in Intestinal Fibroblasts and Monocytes via High Affinity IgG Receptor CD64. <i>Gastroenterology</i> , 2011, 140, S-837.	0.6	0
385	Expression of the G Protein-Coupled Receptor 68 is Increased by TNF-Mediated Inflammatory Signalling. <i>Gastroenterology</i> , 2011, 140, S-837-S-838.	0.6	0
386	Lessons from a transplant patient with diarrhea, cryptosporidial infection, and possible mycophenolate mofetil-associated colitis. <i>Transplant Infectious Disease</i> , 2011, 13, 416-418.	0.7	8
387	Use of biological molecules in the treatment of inflammatory bowel disease. <i>Journal of Internal Medicine</i> , 2011, 270, 15-28.	2.7	34
388	Irritable Bowel Syndrome Among a Cohort of European Travelers to Resource-Limited Destinations. <i>Journal of Travel Medicine</i> , 2011, 18, 250-256.	1.4	49
389	Bilberries and their anthocyanins ameliorate experimental colitis. <i>Molecular Nutrition and Food Research</i> , 2011, 55, 1724-1729.	1.5	60
390	Specific differences in migratory function of myofibroblasts isolated from Crohn's disease fistulae and strictures. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 202-212.	0.9	33
391	Efficacy and safety of certolizumab pegol in an unselected Crohn's disease population. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 1530-1539.	0.9	23
392	Potential role for SNAIL family transcription factors in the etiology of Crohn's disease-associated fistulae. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 1907-1916.	0.9	51
393	Dying in Yoghurt: The Number of Living Bacteria in Probiotic Yoghurt Decreases under Exposure to Room Temperature. <i>Digestion</i> , 2011, 83, 13-17.	1.2	6
394	Is This Stricture Inflammatory?. <i>Digestion</i> , 2011, 83, 261-262.	1.2	0
395	Prebiotics and Probiotics in Ulcerative Colitis: Where Do We Stand?. <i>Digestion</i> , 2011, 84, 126-127.	1.2	1
396	"Red Alert" or Not? "Do We Give Our Inflammatory Bowel Disease Patients the Right Dietary Recommendations?. <i>Digestion</i> , 2011, 84, 236-237.	1.2	2

#	ARTICLE	IF	CITATIONS
397	BCL-2 Modifying Factor (BMF) Is a Central Regulator of Anoikis in Human Intestinal Epithelial Cells. <i>Journal of Biological Chemistry</i> , 2011, 286, 26533-26540.	1.6	42
398	Pathogenesis of Strictures in Ulcerative Colitis: A Field to Explore. <i>Digestion</i> , 2011, 84, 10-11.	1.2	11
399	Frequency and Risk Factors for Extraintestinal Manifestations in the Swiss Inflammatory Bowel Disease Cohort. <i>American Journal of Gastroenterology</i> , 2011, 106, 110-119.	0.2	410
400	Sphingomyelin induces cathepsin D-mediated apoptosis in intestinal epithelial cells and increases inflammation in DSS colitis. <i>Gut</i> , 2011, 60, 55-65.	6.1	74
401	Lack of transketolase-like (TKTL) 1 aggravates murine experimental colitis. <i>American Journal of Physiology - Renal Physiology</i> , 2011, 300, G598-G607.	1.6	10
402	A role for interleukin-33 in TH2-polarized intestinal inflammation?. <i>Mucosal Immunology</i> , 2011, 4, 496-502.	2.7	38
403	Characterization of Changes in Serum Anti-Glycan Antibodies in Crohn's Disease – a Longitudinal Analysis. <i>PLoS ONE</i> , 2011, 6, e18172.	1.1	29
404	Serological Markers in Inflammatory Bowel Disease. , 2011, , 9-20.		0
405	Treatment algorithm for moderate to severe ulcerative colitis. <i>Swiss Medical Weekly</i> , 2011, 141, w13235.	0.8	7
406	Infliximab for Crohn's disease in the Swiss IBD Cohort Study. <i>European Journal of Gastroenterology and Hepatology</i> , 2010, 22, 1352-1357.	0.8	9
407	Expression of growth factor receptors and targeting of EGFR in cholangiocarcinoma cell lines. <i>BMC Cancer</i> , 2010, 10, 302.	1.1	43
408	Association of the novel serologic anti-glycan antibodies anti-laminarin and anti-chitin with complicated Crohn's disease behavior. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 263-274.	0.9	87
409	Circulating levels of chemerin and adiponectin are higher in ulcerative colitis and chemerin is elevated in Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 630-637.	0.9	129
410	Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 933-938.	0.9	27
411	Serum anti-glycan antibodies predict complicated Crohn's disease behavior. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 1367-1375.	0.9	79
412	Association of the NOD2 genotype with bacterial translocation via altered cell-cell contacts in Crohn's disease patients. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 1311-1321.	0.9	38
413	Prostaglandin E2 inhibits migration of colonic lamina propria fibroblasts. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 1505-1513.	0.9	33
414	Gastrointestinal and liver adverse effects of drugs used for treating IBD. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2010, 24, 157-165.	1.0	124

#	ARTICLE	IF	CITATIONS
415	Appropriateness of therapy for fistulizing Crohn's disease: findings from a national inflammatory bowel disease cohort. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 1007-1016.	1.9	9
416	Decreased Cytosolic Glucocorticoid Receptor Levels in Critically Ill Patients. <i>Anaesthesia and Intensive Care</i> , 2010, 38, 133-140.	0.2	25
417	The importance of gut microbiota in mediating the effect of NOD2 defects in inflammatory bowel disease. <i>Gut</i> , 2010, 59, 153-154.	6.1	13
418	Is Inflammatory Bowel Disease More Severe when It Appears at Younger Ages?. <i>Digestion</i> , 2010, 81, 235-236.	1.2	0
419	Microbial Sensing by the Intestinal Epithelium in the Pathogenesis of Inflammatory Bowel Disease. <i>International Journal of Inflammation</i> , 2010, 2010, 1-12.	0.9	17
420	Clinical Relevance of IgG Antibodies against Food Antigens in Crohn's Disease: A Double-Blind Cross-Over Diet Intervention Study. <i>Digestion</i> , 2010, 81, 252-264.	1.2	62
421	Recognition of commensal microbes: if innate responses are NOD in balance. <i>Expert Review of Clinical Immunology</i> , 2010, 6, 205-210.	1.3	1
422	Fistula Treatment: The Unresolved Challenge. <i>Digestive Diseases</i> , 2010, 28, 556-564.	0.8	21
423	The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. <i>Journal of Crohn's and Colitis</i> , 2010, 4, 7-27.	0.6	1,050
424	Prevalence of anaemia in inflammatory bowel disease in Switzerland: A cross-sectional study in patients from private practices and university hospitals. <i>Journal of Crohn's and Colitis</i> , 2010, 4, 642-648.	0.6	57
425	S1211 Extraintestinal Manifestations in Inflammatory Bowel Disease: Frequency and Associated Risk Factors in the Nationwide Swiss IBD Cohort Study (SIBDCS). <i>Gastroenterology</i> , 2010, 138, S-205.	0.6	0
426	Collagen XVI induces formation of focal contacts on intestinal myofibroblasts isolated from the normal and inflamed intestinal tract. <i>Matrix Biology</i> , 2010, 29, 177-193.	1.5	26
427	Clinical Experience with Adalimumab in a Multicenter Swiss Cohort of Patients with Crohn's Disease. <i>Digestion</i> , 2010, 81, 78-85.	1.2	18
428	Volcano-like intermittent bleeding activity for seven years from an arterio-enteric fistula on a kidney graft site after pancreas-kidney transplantation: a case report. <i>Journal of Medical Case Reports</i> , 2010, 4, 357.	0.4	5
429	Diagnosis and management of fistulizing Crohn's disease. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2009, 6, 92-106.	1.7	104
430	Treatment of Severe Ulcerative Colitis: Differences in Elderly Patients?. <i>Digestive Diseases</i> , 2009, 27, 315-321.	0.8	17
431	Medical Management of Ulcerative Colitis. <i>Digestive Diseases</i> , 2009, 27, 542-549.	0.8	21
432	Preface. <i>Digestive Diseases</i> , 2009, 27, 205-205.	0.8	1

#	ARTICLE	IF	CITATIONS
433	Partial Replacement of Dietary (n-6) Fatty Acids with Medium-Chain Triglycerides Decreases the Incidence of Spontaneous Colitis in Interleukin-10-Deficient Mice. <i>Journal of Nutrition</i> , 2009, 139, 603-610.	1.3	36
434	Functional characterisation of decoy receptor 3 in Crohn's disease. <i>Gut</i> , 2009, 58, 483-491.	6.1	57
435	Hepatic failure due to hepatitis B reactivation in a patient with ulcerative colitis treated with prednisone. <i>Hepatology</i> , 2009, 50, 653-654.	3.6	31
436	Gene expression profiles of mucosal fibroblasts from strictured and nonstrictured areas of patients with Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 212-223.	0.9	15
437	Afferent nerve sensitivity is decreased by an iNOS-dependent mechanism during indomethacin-induced inflammation in the murine jejunum <i>in vitro</i> . <i>Neurogastroenterology and Motility</i> , 2009, 21, 322-334.	1.6	17
438	Differential afferent sensitivity to mucosal lipopolysaccharide from <i>Salmonella typhimurium</i> and <i>Escherichia coli</i> in the rat jejunum. <i>Neurogastroenterology and Motility</i> , 2009, 21, 1335.	1.6	11
439	CpG-oligodeoxynucleotides stimulate immunoglobulin A secretion in intestinal mucosal B cells. <i>Clinical and Experimental Immunology</i> , 2009, 155, 534-540.	1.1	44
440	Primary human colonic epithelial cells are transiently protected from anoikis by a Src-dependent mechanism. <i>Biochemical and Biophysical Research Communications</i> , 2009, 390, 908-914.	1.0	7
441	Protection of Epithelial Barrier Function by the Crohn's Disease Associated Gene Protein Tyrosine Phosphatase N2. <i>Gastroenterology</i> , 2009, 137, 2030-2040.e5.	0.6	100
442	Transforming growth factor- β 1 induces intestinal myofibroblast differentiation and modulates their migration. <i>World Journal of Gastroenterology</i> , 2009, 15, 1431.	1.4	77
443	Recipient NOD2/CARD15 status affects cellular infiltrates in human intestinal graft-versus-host disease. <i>Clinical and Experimental Immunology</i> , 2009, 159, 87-92.	1.1	29
444	Frequency and Nature of Incidental Extra-Enteric Lesions Found on Magnetic Resonance Enterography (MR-E) in Patients with Inflammatory Bowel Diseases (IBD). <i>PLoS ONE</i> , 2009, 4, e4863.	1.1	20
445	Serum bile acid profiling reflects enterohepatic detoxification state and intestinal barrier function in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2009, 15, 3134.	1.4	67
446	Anthocyanins and anthocyanidins are poor inhibitors of CYP2D6. <i>Methods and Findings in Experimental and Clinical Pharmacology</i> , 2009, 31, 3.	0.8	2
447	Inflammation modulates fibronectin isoform expression in colonic lamina propria fibroblasts (CLPF). <i>International Journal of Colorectal Disease</i> , 2008, 23, 947-955.	1.0	16
448	Evidence for a role of epithelial mesenchymal transition during pathogenesis of fistulae in Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 1514-1527.	0.9	117
449	Regulation of galectin-3 function in mucosal fibroblasts: potential role in mucosal inflammation. <i>Clinical and Experimental Immunology</i> , 2008, 152, 285-297.	1.1	36
450	(GT) _n Dinucleotide repeat polymorphism of haem oxygenase-1 promotor region is not associated with inflammatory bowel disease risk or disease course. <i>Clinical and Experimental Immunology</i> , 2008, 153, 81-85.	1.1	12

#	ARTICLE	IF	CITATIONS
451	Recipient NOD2/CARD15 Variants: A Novel Independent Risk Factor for the Development of Bronchiolitis Obliterans after Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 67-74.	2.0	54
452	Inhibition of proteasome activity by anthocyanins and anthocyanidins. <i>Biochemical and Biophysical Research Communications</i> , 2008, 372, 57-61.	1.0	48
453	Do We Need Gastric Acid?. <i>Digestion</i> , 2008, 77, 184-197.	1.2	37
454	NOD2/CARD15 Polymorphisms in Allogeneic Stem-Cell Transplantation From Unrelated Donors: T Depletion Matters. <i>Journal of Clinical Oncology</i> , 2008, 26, 338-339.	0.8	16
455	NAT1 Genotypes Do not Predict Response to Mesalamine in Patients with Ulcerative Colitis. <i>Zeitschrift Fur Gastroenterologie</i> , 2008, 46, 259-265.	0.2	8
456	The incidence of inflammatory bowel disease in a rural region of Southern Germany: a prospective population-based study. <i>European Journal of Gastroenterology and Hepatology</i> , 2008, 20, 917-923.	0.8	93
457	Immune-non Immune Networks in Intestinal Inflammation. <i>Current Drug Targets</i> , 2008, 9, 388-394.	1.0	11
458	The role of domestic hygiene in inflammatory bowel diseases: hepatitis A and worm infestations. <i>European Journal of Gastroenterology and Hepatology</i> , 2008, 20, 561-566.	0.8	21
459	Wound healing and fibrosis in intestinal disease. <i>Gut</i> , 2007, 56, 130-139.	6.1	262
460	Glucocorticoid receptor isoform expression does not predict steroid treatment response in IBD. <i>Gut</i> , 2007, 56, 1328-1329.	6.1	19
461	A case of recurrent gastrointestinal bleeding and protein-losing gastroenteropathy. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2007, 4, 288-293.	1.7	17
462	Soluble galectin-3 is a strong, colonic epithelial-cell-derived, lamina propria fibroblast-stimulating factor. <i>Gut</i> , 2007, 56, 43-51.	6.1	57
463	299: The role of SNPs within receptors of innate immunity in outcome following allogeneic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 108-109.	2.0	1
464	Differential Protein Expression Profile in the Intestinal Epithelium from Patients with Inflammatory Bowel Disease. <i>Journal of Proteome Research</i> , 2007, 6, 1114-1125.	1.8	111
465	Sexual Function in Persons With Inflammatory Bowel Disease: A Survey With Matched Controls. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 87-94.	2.4	122
466	Interleukin-10 Blocked Endoplasmic Reticulum Stress in Intestinal Epithelial Cells: Impact on Chronic Inflammation. <i>Gastroenterology</i> , 2007, 132, 190-207.	0.6	255
467	Cell-Cell Contacts Prevent Anoikis in Primary Human Colonic Epithelial Cells. <i>Gastroenterology</i> , 2007, 132, 587-600.	0.6	127
468	The effects of NOD2/CARD15 mutations on the function of the intestinal barrier. <i>Journal of Crohn's and Colitis</i> , 2007, 1, 53-60.	0.6	17

#	ARTICLE	IF	CITATIONS
469	Serum soluble TNF receptor I and II levels correlate with disease activity in IBD patients. <i>Inflammatory Bowel Diseases</i> , 2007, 13, 727-732.	0.9	66
470	Determinants of male sexual function in inflammatory bowel disease: A survey-based cross-sectional analysis in 280 men. <i>Inflammatory Bowel Diseases</i> , 2007, 13, 1236-1243.	0.9	69
471	<i>In vivo</i> treatment with the herbal phenylethanoid acteoside ameliorates intestinal inflammation in dextran sulphate sodium-induced colitis. <i>Clinical and Experimental Immunology</i> , 2007, 148, 373-381.	1.1	141
472	13-Oxo-ODE is an endogenous ligand for PPAR β in human colonic epithelial cells. <i>Biochemical Pharmacology</i> , 2007, 74, 612-622.	2.0	104
473	Genetic variants in the NOD2/CARD15 gene are associated with early mortality in sepsis patients. <i>Intensive Care Medicine</i> , 2007, 33, 1541-1548.	3.9	60
474	(E)-metanicotine hemigalactarate (TC-2403-12) inhibits IL-8 production in cells of the inflamed mucosa. <i>International Journal of Colorectal Disease</i> , 2007, 22, 303-312.	1.0	7
475	Evidence for a differential expression of fibronectin splice forms ED-A and ED-B in Crohn's disease (CD) mucosa. <i>International Journal of Colorectal Disease</i> , 2007, 22, 611-623.	1.0	25
476	Probiotic <i>Escherichia coli</i> Nissle 1917 Inhibits Leaky Gut by Enhancing Mucosal Integrity. <i>PLoS ONE</i> , 2007, 2, e1308.	1.1	386
477	Exogenous sphingomyelinase causes impaired intestinal epithelial barrier function. <i>World Journal of Gastroenterology</i> , 2007, 13, 5217.	1.4	30
478	Role of soluble factors and three-dimensional culture in <i>in vitro</i> differentiation of intestinal macrophages. <i>World Journal of Gastroenterology</i> , 2007, 13, 1032.	1.4	11
479	Polymorphisms Within Epithelial Receptors. <i>Methods in Molecular Medicine</i> , 2007, 134, 115-121.	0.8	0
480	Interleukin 10 blocked endoplasmic reticulum stress in intestinal epithelial cells: impact on chronic inflammation. <i>FASEB Journal</i> , 2007, 21, A589.	0.2	0
481	Prognostic significance of NOD2/CARD15 variants in HLA-identical sibling hematopoietic stem cell transplantation: effect on long-term outcome is confirmed in 2 independent cohorts and may be modulated by the type of gastrointestinal decontamination. <i>Blood</i> , 2006, 107, 4189-4193.	0.6	170
482	Multiparameter Immunofluorescence on Paraffin-Embedded Tissue Sections. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2006, 14, 225-228.	0.6	27
483	Epithelial Response. <i>Inflammatory Bowel Diseases</i> , 2006, 12, S6-S7.	0.9	0
484	NOD2/CARD15 Mutations Associate With Transplant-related Mortality and GvHD in HLA-Identical Sibling Transplants. <i>Inflammatory Bowel Diseases</i> , 2006, 12, S19.	0.9	0
485	A new organotypic model to study cell interactions in the intestinal mucosa. <i>European Journal of Gastroenterology and Hepatology</i> , 2006, 18, 901-909.	0.8	15
486	Secretion of RANTES (CCL5) and interleukin-10 from mesenteric adipose tissue and from creeping fat in Crohn's disease: Regulation by steroid treatment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2006, 21, 060606032707058-???	1.4	32

#	ARTICLE	IF	CITATIONS
487	Vascular endothelial growth factor secretion from mesenteric adipose tissue and from creeping fat in Crohn's disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2006, 21, 060606032707048-???	1.4	17
488	Monocyte chemoattractant protein-1 (MCP-1) inhibits the intestinal-like differentiation of monocytes. <i>Clinical and Experimental Immunology</i> , 2006, 145, 190-199.	1.1	44
489	Cathepsins B, L and D in inflammatory bowel disease macrophages and potential therapeutic effects of cathepsin inhibition in vivo. <i>Clinical and Experimental Immunology</i> , 2006, 146, 169-180.	1.1	104
490	Profiling adipocytokine secretion from creeping fat in Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2006, 12, 471-477.	0.9	118
491	Functional expression of the interleukin-11 receptor alpha-chain in normal colonic epithelium and colon cancer. <i>International Journal of Colorectal Disease</i> , 2006, 21, 573-581.	1.0	9
492	Comparison of capsule endoscopy and magnetic resonance (MR) enteroclysis in suspected small bowel disease. <i>International Journal of Colorectal Disease</i> , 2006, 21, 97-104.	1.0	167
493	Serum antibodies to EpCAM in healthy donors but not ulcerative colitis patients. <i>Cancer Immunology, Immunotherapy</i> , 2006, 55, 528-537.	2.0	6
494	IL-15 protects intestinal epithelial cells. <i>European Journal of Immunology</i> , 2006, 36, 2691-2699.	1.6	38
495	Crohn's Disease of the Esophagus: Treatment of an Esophagobronchial Fistula with the Novel Liquid Embolic Polymer Onyx. <i>Zeitschrift Fur Gastroenterologie</i> , 2006, 44, 599-602.	0.2	14
496	Association of antibodies to exocrine pancreas with subtypes of Crohn's disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2005, 17, 73-77.	0.8	42
497	Coombs-positive autoimmune hemolytic anemia in Crohn's disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2005, 17, 661-666.	0.8	14
498	Crohn's disease patient characteristics in a tertiary referral center: comparison with patients from a population-based cohort. <i>European Journal of Gastroenterology and Hepatology</i> , 2005, 17, 395-401.	0.8	44
499	Analysis of intestinal haem-oxygenase-1 (HO-1) in clinical and experimental colitis. <i>Clinical and Experimental Immunology</i> , 2005, 140, 547-555.	1.1	115
500	Dark Lumen Magnetic Resonance Enteroclysis in Combination With Mri Colonography for Whole Bowel Assessment in Patients With Crohn's Disease: First Clinical Experience. <i>Inflammatory Bowel Diseases</i> , 2005, 11, 388-394.	0.9	81
501	Strong expression of methylthioadenosine phosphorylase (MTAP) in human colon carcinoma cells is regulated by TCF1/ β -catenin. <i>Laboratory Investigation</i> , 2005, 85, 124-136.	1.7	21
502	Bile salt-induced apoptosis in human colon cancer cell lines involves the mitochondrial transmembrane potential but not the CD95 (Fas/Apo-1) receptor. <i>International Journal of Colorectal Disease</i> , 2005, 20, 103-113.	1.0	34
503	Significance of anti-inflammatory effects of PPAR α agonists?. <i>Gut</i> , 2005, 55, 1067-1069.	6.1	15
504	A Janus-Headed Polyp: Adenoma and Carcinoma with a Single Stalk. <i>Endoscopy</i> , 2005, 37, 96-96.	1.0	0

#	ARTICLE	IF	CITATIONS
505	Physiological Role of Macrophage Inflammatory Protein-3 β Induction during Maturation of Intestinal Macrophages. <i>Journal of Immunology</i> , 2005, 175, 1389-1398.	0.4	19
506	Glycoprotein (gp) 96 expression: induced during differentiation of intestinal macrophages but impaired in Crohn's disease. <i>Gut</i> , 2005, 54, 935-943.	6.1	26
507	Epidermal Growth Factor Partially Restores Colonic Ion Transport Responses in Mouse Models of Chronic Colitis. <i>Gastroenterology</i> , 2005, 129, 591-608.	0.6	55
508	Comparison of magnetic resonance imaging colonography with conventional colonoscopy for the assessment of intestinal inflammation in patients with inflammatory bowel disease: a feasibility study. <i>Gut</i> , 2005, 54, 250-256.	6.1	112
509	Epidermal Growth Factor Partially Restores Colonic Ion Transport Responses in Mouse Models of Chronic Colitis. <i>Gastroenterology</i> , 2005, 129, 591-608.	0.6	44
510	CpG Motifs of Bacterial DNA Essentially Contribute to the Perpetuation of Chronic Intestinal Inflammation. <i>Gastroenterology</i> , 2005, 129, 913-927.	0.6	98
511	Ephrin-B2 is differentially expressed in the intestinal epithelium in Crohn's disease and contributes to accelerated epithelial wound healing in vitro. <i>World Journal of Gastroenterology</i> , 2005, 11, 4024.	1.4	38
512	NOD2/CARD15 Variants of Donor and Recipient as Critical Risk Factors for the Development of Bronchiolitis Obliterans Syndrome after Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2005, 106, 144-144.	0.6	4
513	Use of Self-Expandable Plastic Stents For the Treatment of Esophageal Perforations and Symptomatic Anastomotic Leaks. <i>Endoscopy</i> , 2004, 36, 695-699.	1.0	204
514	Functional Expression of the Interleukin-11 Receptor α -Chain and Evidence of Antiapoptotic Effects in Human Colonic Epithelial Cells. <i>Journal of Biological Chemistry</i> , 2004, 279, 10304-10315.	1.6	58
515	Morphological characterisation of Crohn's disease fistulae. <i>Gut</i> , 2004, 53, 1314-1321.	6.1	109
516	Autocrine Fibronectin-Induced Migration of Human Colonic Fibroblasts. <i>American Journal of Gastroenterology</i> , 2004, 99, 335-340.	0.2	50
517	Can NOD2/CARD15 mutations predict intestinal graft-versus-host disease and aid our understanding of Crohn's disease?. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2004, 1, 62-63.	1.7	8
518	Cathepsin D is up-regulated in inflammatory bowel disease macrophages. <i>Clinical and Experimental Immunology</i> , 2004, 136, 157-167.	1.1	50
519	Modern Imaging Using Computer Tomography and Magnetic Resonance Imaging for Inflammatory Bowel Disease (IBD) AU1. <i>Inflammatory Bowel Diseases</i> , 2004, 10, 45-54.	0.9	77
520	Intracellular Polyamine Levels of Intestinal Epithelial Cells in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2004, 10, 529-535.	0.9	50
521	Optimising the diagnostic value of Anti- <i>Saccharomyces cerevisiae</i> -antibodies (ASCA) in Crohn's disease. <i>International Journal of Colorectal Disease</i> , 2004, 19, 319-324.	1.0	22
522	Interferon gamma downregulates IL-8 production in primary human colonic epithelial cells without induction of apoptosis. <i>International Journal of Colorectal Disease</i> , 2004, 19, 421-9.	1.0	10

#	ARTICLE	IF	CITATIONS
523	Abdominal MRI after enteroclysis or with oral contrast in patients with suspected or proven Crohn's disease. <i>Clinical Gastroenterology and Hepatology</i> , 2004, 2, 491-497.	2.4	170
524	Update in inflammatory bowel disease pathogenesis. <i>Current Opinion in Gastroenterology</i> , 2004, 20, 311-317.	1.0	67
525	Both donor and recipient NOD2/CARD15 mutations associate with transplant-related mortality and GvHD following allogeneic stem cell transplantation. <i>Blood</i> , 2004, 104, 889-894.	0.6	266
526	NOD2/CARD15 Mutations Associate with Transplant Related Mortality and GvHD in HLA-Identical Sibling Transplants: Detailed Analysis of Single SNPs in 211 Recipient/Donor Pairs. <i>Blood</i> , 2004, 104, 424-424.	0.6	0
527	Polymorphism of monocyte chemoattractant protein 1 in Crohn's disease. <i>International Journal of Colorectal Disease</i> , 2003, 18, 401-405.	1.0	31
528	Sonographische Kontrolle von Magensonden bei Intensivpatienten. <i>Intensivmedizin Und Notfallmedizin</i> , 2003, 40, 693-697.	0.2	6
529	Patients with refractory Crohn's disease or ulcerative colitis respond to dehydroepiandrosterone: a pilot study. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 17, 409-414.	1.9	44
530	Inverse regulation of the ADAM-family members, decysin and MADDAM/ADAM19 during monocyte differentiation. <i>Immunology</i> , 2003, 110, 450-457.	2.0	34
531	Association of Perinuclear Antineutrophil Cytoplasmic Antibodies and Anti-Saccharomyces cerevisiae Antibodies With Vienna Classification Subtypes of Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2003, 9, 302-307.	0.9	54
532	The expression of fibronectin splicing-forms ED-A and ED-B is reduced in IBD mucosa. <i>Gastroenterology</i> , 2003, 124, A331.	0.6	0
533	Regulation of the adipocyte specific protein APM-1 in inflammatory bowel disease. <i>Gastroenterology</i> , 2003, 124, A325.	0.6	0
534	The glycoprotein (gp) 96 is absent in intestinal macrophages from patients with inflammatory bowel disease (IBD). <i>Gastroenterology</i> , 2003, 124, A497.	0.6	0
535	The migratory potential of Crohn's disease myofibroblasts differs significantly between inflamed mucosa, strictures and fistulae. <i>Gastroenterology</i> , 2003, 124, A329.	0.6	0
536	Identification and quantification of soluble TNF receptors I and II in serum of IBD patients. <i>Gastroenterology</i> , 2003, 124, A336.	0.6	0
537	Cathepsin D contributes to mucosal damage in inflammatory bowel disease. <i>Gastroenterology</i> , 2003, 124, A325.	0.6	0
538	Specific differences in the cytokine/receptor expression pattern of Crohn's disease mast cells and mast cells from normal mucosa. <i>Gastroenterology</i> , 2003, 124, A335-A336.	0.6	0
539	Reduced migration of fibroblasts in inflammatory bowel disease: role of inflammatory mediators and focal adhesion kinase1 The authors thank Dr. Luitpold E. Miller for his assistance in the preparation of this manuscript; the doctors and nurses of the Endoscopy department; the surgeons and pathologists of the University of Regensburg, especially Dr. Frauke Bataille, for their ongoing great cooperation; and, most importantly, all patients who agreed to give biopsy and tissue samples, without whom this study. <i>Gastroenterology</i> , 2003, 125, 1341-1354.	0.6	91
540	Progress on isolation and short-term ex-vivo culture of highly purified non-apoptotic human intestinal epithelial cells (IEC). <i>European Journal of Cell Biology</i> , 2003, 82, 262-270.	1.6	50

#	ARTICLE	IF	CITATIONS
541	Inducible CD40 expression mediates NF κ B activation and cytokine secretion in human colonic fibroblasts. <i>Gut</i> , 2003, 52, 1448-1456.	6.1	55
542	Orofacial Granulomatosis as the Initial Presentation of Crohn's Disease in an Adolescent. <i>Dermatology</i> , 2003, 206, 273-278.	0.9	58
543	Genomics and inductive reasoning: Revolution, renaissance, or rhetoric?. <i>Genetics in Medicine</i> , 2003, 5, 476-478.	1.1	1
544	Stimulation of human colonic epithelial cells by leukemia inhibitory factor is dependent on collagen-embedded fibroblasts in organotypic culture. <i>FASEB Journal</i> , 2003, 17, 1115-1117.	0.2	31
545	Treatment of Pouchitis with Dehydroepiandrosterone (DHEA) - a Case Report. <i>Zeitschrift Fur Gastroenterologie</i> , 2003, 41, 1087-1090.	0.2	7
546	Multi-site therapeutic modalities for inflammatory bowel diseases " mechanisms of action. , 2003, , 523-551.		0
547	Multi-site therapeutic modalities for inflammatory bowel diseases " mechanisms of action. , 2003, , 523-551.		0
548	Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, open-label, multicenter trial in refractory Crohn's disease. <i>American Journal of Gastroenterology</i> , 2002, 97, 2688-2690.	0.2	104
549	Regulation of Migration of Human Colonic Myofibroblasts. <i>Growth Factors</i> , 2002, 20, 81-91.	0.5	75
550	Association of HLA-DR genotypes and IL-1ra gene polymorphism with treatment failure of budesonide and disease patterns in Crohn's disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2001, 13, 1431-1437.	0.8	16
551	Subtractive screening reveals up-regulation of NADPH oxidase expression in Crohn's disease intestinal macrophages. <i>Clinical and Experimental Immunology</i> , 2001, 125, 48-55.	1.1	50
552	Differential Activation of Cytokine Secretion in Primary Human Colonic Fibroblast/Myofibroblast Cultures. <i>Scandinavian Journal of Gastroenterology</i> , 2001, 36, 389-398.	0.6	61
553	Nuclear factor- κ B activity and intestinal inflammation in dextran sulphate sodium (DSS)-induced colitis in mice is suppressed by gliotoxin. <i>Clinical and Experimental Immunology</i> , 2000, 120, 59-65.	1.1	72
554	Human intestinal epithelial cells secrete interleukin-1 receptor antagonist and interleukin-8 but not interleukin-1 or interleukin-6. <i>Gut</i> , 2000, 46, 350-358.	6.1	89
555	Intracellular Transport of High-Density Lipoprotein 3 in Intestinal Epithelial Cells (Caco-2) Is Tubulin Associated. <i>Digestion</i> , 2000, 61, 47-58.	1.2	4
556	Intestinal epithelial cells induce selection of a small subpopulation of monocytes during coculture. <i>Gastroenterology</i> , 2000, 118, A1371.	0.6	0
557	Induction of toll-like receptor 2 in human intestinal myofibroblasts by interferon gamma. <i>Gastroenterology</i> , 2000, 118, A791.	0.6	1
558	Secretion and expression of IL-8 in IFN γ stimulated human colonic epithelial cells depends on cell differentiation. <i>Gastroenterology</i> , 2000, 118, A603.	0.6	0

#	ARTICLE	IF	CITATIONS
559	Subtractive screening reveals increased expression of cathepsin D in intestinal macrophages from inflammatory bowel disease mucosa. <i>Gastroenterology</i> , 2000, 118, A345.	0.6	0
560	Platelet activation in patients with inflammatory bowel disease. <i>Gastroenterology</i> , 2000, 118, A1359.	0.6	0
561	Intestinal graft versus host disease detected and monitored by ultrasound. <i>Gastroenterology</i> , 2000, 118, A1411.	0.6	0
562	Analysis of a novel polymorphism in the MCP-1 gene: Influence on mucosal MCP-1 expression and disease activity in IBD. <i>Gastroenterology</i> , 2000, 118, A799.	0.6	0
563	A three dimensional organotypic model for the study of cell interaction in the intestinal mucosa. <i>Gastroenterology</i> , 2000, 118, A362.	0.6	0
564	Bile salt induced apoptosis in colon cancer cell lines: Mechanisms and differences to primary colon epithelial cells. <i>Gastroenterology</i> , 2000, 118, A553.	0.6	0
565	Systemic caspase-inhibitors severely aggravate colitis in rodent models of colitis. <i>Gastroenterology</i> , 2000, 118, A1135.	0.6	0
566	Correlation between nickel allergy towards dentures and Crohn's disease: A case report. <i>Gastroenterology</i> , 2000, 118, A1135.	0.6	0
567	Downregulation of IL-1beta RNA in monocytes/macrophages during coculture with intestinal epithelial cells. <i>Gastroenterology</i> , 2000, 118, A1137.	0.6	0
568	Bile acid mediated apoptosis in human colon cancer cell lines is not mediated via the CD95/Fas/Apo-1 pathway. <i>Gastroenterology</i> , 2000, 118, A1140.	0.6	0
569	IFN-b variously regulates IL-8 secretion in human colonic myofibroblasts and in primary human colonic epithelial cells. <i>Gastroenterology</i> , 2000, 118, A109.	0.6	0
570	Growth and Cell Cycle Abnormalities of Fibroblasts From Tangier Disease Patients. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1999, 19, 28-38.	1.1	40
571	Glucocorticoid receptors are down-regulated in inflamed colonic mucosa but not in peripheral blood mononuclear cells from patients with inflammatory bowel disease. <i>European Journal of Clinical Investigation</i> , 1999, 29, 330-336.	1.7	45
572	T-cell co-stimulatory molecules are upregulated on intestinal macrophages from inflammatory bowel disease mucosa. <i>European Journal of Gastroenterology and Hepatology</i> , 1999, 11, 1105-1112.	0.8	48
573	Cytokines in Inflammatory Bowel Disease. <i>World Journal of Surgery</i> , 1998, 22, 382-389.	0.8	447
574	Isolation and phenotypic characterization of colonic macrophages. <i>Clinical and Experimental Immunology</i> , 1998, 112, 205-215.	1.1	164
575	Nuclear factor κ B is activated in macrophages and epithelial cells of inflamed intestinal mucosa. <i>Gastroenterology</i> , 1998, 115, 357-369.	0.6	661
576	Late onset primary oxalosis type I. <i>European Journal of Gastroenterology and Hepatology</i> , 1998, 10, 809-812.	0.8	2

#	ARTICLE	IF	CITATIONS
577	The Trp64Arg Polymorphism of the β 3-Adrenergic Receptor Gene Is Not Associated with Obesity or Type 2 Diabetes Mellitus in a Large Population-Based Caucasian Cohort. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 2892-2897.	1.8	59
578	Alterations of the phenotype of colonic macrophages in inflammatory bowel disease. <i>European Journal of Gastroenterology and Hepatology</i> , 1997, 9, 893-899.	0.8	68
579	Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion.. <i>Journal of Clinical Investigation</i> , 1996, 97, 1715-1722.	3.9	721
580	Influence of Cholesterol Supply on Cell Growth and Differentiation in Cultured Enterocytes (CaCo-2). <i>Digestion</i> , 1995, 56, 57-66.	1.2	17
581	Mevalonate is essential for growth of porcine and human vascular smooth muscle cells in vitro. <i>Basic Research in Cardiology</i> , 1995, 90, 443-450.	2.5	8
582	HDL-Mediated Efflux of Intracellular Cholesterol Is Impaired in Fibroblasts From Tangier Disease Patients. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1995, 15, 683-690.	1.1	101
583	The Defect in HDL3 Mediated Efflux of Newly Synthesized Cholesterol is Associated with Impaired Activation of Protein Kinase C in Tangier Fibroblasts. , 1995, , 79-87.		0
584	Improved separation of radioactively labelled cellular phospholipids by high-performance liquid chromatography. <i>Biomedical Applications</i> , 1994, 656, 73-76.	1.7	8
585	HDL3-mediated cholesterol efflux from cultured enterocytes: The role of apoproteins A-I and A-II. <i>Lipids</i> , 1994, 29, 735-745.	0.7	10
586	Morphology of CaCo-2 cells varies in different cell batches. <i>In Vitro Cellular and Developmental Biology - Animal</i> , 1994, 30, 289-291.	0.7	6
587	High-density lipoprotein 3 retroendocytosis: A new lipoprotein pathway in the enterocyte (Caco-2). <i>Gastroenterology</i> , 1992, 103, 469-480.	0.6	24
588	Regulation of Cholesterol Metabolism and Low-Density Lipoprotein Binding in Human Intestinal Caco-2 Cells. <i>Digestion</i> , 1992, 51, 10-17.	1.2	13
589	HDL3-retroendocytosis in cultured small intestinal crypt cells: a novel mechanism of cholesterol efflux. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1991, 1095, 30-38.	1.9	13